olmesartan medoxomil profile

Olmesartan Medoxomil: An ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to manage HYPERTENSION. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	130881
CHEMBL ID	1200692
CHEBI ID	31932
SCHEMBL ID	16403
MeSH ID	M0257341

Synonym
AC-1601
6m97xtv3hd ,
unii-6m97xtv3hd
olmesartan medoxomil [usan:inn:ban]
olsertain
nsc 758924
HY-17005
BRD-K78485176-001-02-9
gtpl591
openvas
1h-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl) methyl ester
cs-866rn
benicar
olmetec
1h-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-,(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
cs-866dm
olvance
1h-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
olmesartan medoxomil
cs 866
benevas
SPECTRUM_001944
BSPBIO_003491
SPECTRUM5_001556
benicar (tn)
144689-63-4
olmetec (tn)
olmesartan medoxomil (jp17/usp)
D01204
NCGC00095136-02
NCGC00095136-01
cs-866
KBIO2_007626
KBIOGR_001040
KBIO2_002490
KBIO2_005058
KBIO3_002711
KBIOSS_002498
SPECTRUM3_001676
SPECTRUM2_000506
SPBIO_000431
SPECTRUM4_000740
SPECTRUM1505205
HMS2093K16
HMS2089K18
CHEMBL1200692
nsc-758924
L001061
HMS1922L15
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]-4-imidazolecarboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
(5-methyl-2-oxidanylidene-1,3-dioxol-4-yl)methyl 5-(2-oxidanylpropan-2-yl)-2-propyl-3-[[4-[2-(2h-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylate
A808260
NCGC00095136-03
nsc758924
BCP9000555
pharmakon1600-01505205
dtxcid7025924
cas-144689-63-4
dtxsid9045924 ,
tox21_111445
5-(1-hydroxy-1-methylethyl)-2-propyl-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-3h-imidazole-4-carboxylic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester
c29h30n6o6
CCG-39596
FT-0601603
olmesartan medoxomil [usp monograph]
olmesartan medoxomil [inn]
olmesartan medoxomil [vandf]
olmesartan medoxomil component of benicar hct
olmesartan medoxomil [mart.]
olmesartan medoxomil [who-dd]
azor component olmesartan medoxomil
tribenzor component olmesartan medoxomil
olmesartan medoxomil [usp-rs]
olmesartan medoxomil component of azor
1h-imidazole-5-carboxylic acid, 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, (5-methyl-2-oxo-1,3- dioxol-4-yl)methyl ester
olmesartan medoxomil component of tribenzor
olmesartan medoxomil [usan]
olmesartan medoxomil [orange book]
olmesartan medoxomil [ep monograph]
olmesartan medoxomil [jan]
benicar hct component olmesartan medoxomil
CS-0577
S1604
AKOS015894907
AKOS015914772
bdbm50442892
CCG-221184
smr002203616
MLS006010109
SCHEMBL16403
KS-1182 ,
AB01275443-01
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-i midazole-5-carboxylate
J-501595
UQGKUQLKSCSZGY-UHFFFAOYSA-N
(5-methyl-2-oxo-1,3-dioxolen-4yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl]imidazole-5-carboxylate
(5-methyl-2-oxo-1,3-dioxolen-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{4-[2-(tetrazol-5-yl)phenyl]phenyl}methylimidazole-5-carboxylate
olmesartan medoxomil\|4-(1-hydroxy-1-methylethyl)-2-propyl-1-[[2'-(2h-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-1h-imidazole-5-carboxylic acid-(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester
olmesartan medoxomil, pharmaceutical secondary standard; certified reference material
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(2h-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate
AB01275443_03
AB01275443_02
STL451024
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1h-tetrazol-5-yl)biphenyl-4-yl]methyl}-1h-imidazole-5-carboxylate
olmesartan (medoxomil)
medoxomil, olmesartan
cs866
olmesartanmedoxomil
mfcd00944911
SR-05000001987-2
sr-05000001987
olmesartan medoxomil, united states pharmacopeia (usp) reference standard
HMS3651E13
SR-05000001987-1
olmesartan medoxomil, >=98% (hplc)
olmesartan medoxomil, european pharmacopoeia (ep) reference standard
olmesartan medoxomil for system suitability, european pharmacopoeia (ep) reference standard
votume
CHEBI:31932
SBI-0206741.P001
HMS3715N09
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate
SW199650-2
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate
BCP05214
Q27888058
Z1541759904
olmesartan medoxomil (benicar)
O0510
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(2-hydroxy-2-propanyl)-2-propyl-1-[[2'-(1h-tetrazol-5-yl)-4-biphenylyl]methyl]-1h-imidazole-5-carboxylate
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 1-[[2'-(1h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl]-4-(2-hydroxypr
AMY22222
BRD-K78485176-001-03-7
SB19327
olmesartan-medoxomil
HMS3743O09
NCGC00095136-09
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl1-((2'-(2h-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-4-(2-hydroxypropan-2-yl)-2-propyl-1h-imidazole-5-carboxylate
olmesartan-d4medoxomil
EN300-122375
(5-methyl-2-oxo-2h-1,3-dioxol-4-yl)methyl 4-(2-hydroxypropan-2-yl)-2-propyl-1-{[2'-(1h-1,2,3,4-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl]methyl}-1h-imidazole-5-carboxylate
HY-17005R
CS-0694888
olmesartan medoxomil (standard)
olmesartan medoxomil (usp-rs)
olmesartan medoxomil (usp monograph)
5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxy-4-(1-hydroxy-1-methylethyl)-2-propyl-1-(4-(2-(tetrazol-5-yl)phenyl)phenyl)methylimidazol-5-carboxylate-t287346
olmesartan medoxomil (ep monograph)
olmesartan medoxomil (mart.)
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 4-(1-hydroxy-1-methylethyl)-2-propyl-1-((2'-(1h-tetrazol-5-yl)biphenyl-4-yl)methyl)-1h-imidazole-5-carboxylate

Excerpt	Reference	Relevance
"Olmesartan medoxomil is a new non-peptide angiotensin (A) II antagonist under development for treating hypertension. "	( In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. Koike, H; Mizuno, M; Sada, T, 2001)	2.03
"Olmesartan medoxomil (OM) is a prodrug-type angiotensin II type 1 receptor antagonist. "	( Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism. Fujimori, I; Ikeda, T; Ishizuka, T; Izumi, T; Kurihara, A; Nakahara, K; Nishida, A; Sakurai, H; Yoshigae, Y, 2012)	2.07
"Olmesartan medoxomil (OM) is an angiotensin II receptor blocker (ARB) and has been shown to exhibit renoprotective effects on a streptozotocin (STZ)-induced diabetic rat model."	( Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice. Cui, TX; Ding, A; Li, ZL; Yang, H; Zhang, H; Zhang, HT; Zhu, WP; Zhu, Y, 2019)	2.68
"Olmesartan Medoxomil (OM) is an angiotensin receptor blocker and has the adverse effect of celiac like enteropathy which was accepted by the FDA in 2013. "	( Comparison of Pharmacodynamics and Celiac Effects of Olmesartan Medoxomil Formulations by using Olmesartan-induced Celiac-rat-model. Ergur, BU; Karasulu, E; Komesli, Y, 2021)	2.31
"Olmesartan medoxomil is an antihypertensive drug of the class of angiotensin II type 1 (AT1) receptor antagonists (or blockers), characterized by tight and prolonged binding to AT1 receptor compared to other molecules within the same class. "	( Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control. Battistoni, A; Coluccia, R; Mastromarino, V; Santolamazza, C; Tocci, G; Volpe, M, 2017)	1.9
"Olmesartan medoxomil (OLM) is an antihypertensive drug with low oral bioavailability due to extensive first-pass metabolism. "	( Use of transethosomes for enhancing the transdermal delivery of olmesartan medoxomil: in vitro, ex vivo, and in vivo evaluation. Abdelbary, AA; Albash, R; El-Nabarawi, MA; Refai, H, 2019)	2.2
"Olmesartan medoxomil (OM) is a hydrophobic antihypertensive drug with low bioavailability (26%) and is known to have adverse effects such as celiac disease and enteropathy. "	( Design and development of a self-microemulsifying drug delivery system of olmesartan medoxomil for enhanced bioavailability. Burak Ozkaya, A; Karasulu, E; Kirilmaz, L; Komesli, Y; Ugur Ergur, B, 2019)	2.19
"Olmesartan medoxomil (OLM) is a promising prodrug hydrolyzed to olmesartan (OL) during absorption from the gastrointestinal tract. "	( In Vitro and In Vivo Evaluation of Olmesartan Medoxomil Microcrysta ls and Nanocrystals: Preparation, Characterization, and Pharmacokinet ic Comparison in Beagle Dogs. Chai, R; Fu, Q; Gao, H; Guo, M; He, Z; Liu, H; Ma, Z, 2019)	2.23
"Olmesartan medoxomil (OM) is a prodrug-type angiotensin II type 1 receptor blocker (ARB). "	( Different hydrolases involved in bioactivation of prodrug-type angiotensin receptor blockers: carboxymethylenebutenolidase and carboxylesterase 1. Ishizuka, T; Izumi, T; Murayama, N; Yoshigae, Y, 2013)	1.83
"Olmesartan medoxomil is an orally given angiotensin II receptor antagonist indicated for the treatment of hypertension."	( Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension. Kodati, D; Kotakonda, HK; Yellu, N, 2017)	2.13
"Olmesartan medoxomil (OLM) is an antihypertensive drug with low oral bioavailability (28%) resulting from poor aqueous solubility, presystemic metabolism and P-glycoprotein mediated efflux. "	( Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation. Chella, N; Kulhari, H; Nooli, M; Shastri, NR; Sistla, R, 2017)	2.14
"Olmesartan medoxomil is a new angiotensin-2 receptor blocker (ARB). "	( Pharmacokinetics of olmesartan medoxomil in hemodialysis patients: little effect of dialysis upon its pharmacokinetics. Hamano, T; Horio, M; Imai, E; Isaka, Y; Ito, T; Iwatani, H; Kawada, N; Matsui, I; Nagasawa, Y; Tanaka, H, 2009)	2.12
"Olmesartan medoxomil is a long-acting, well-tolerated, effective ARB that prevents or reverses endothelial dysfunction in animal models of atherosclerosis, hypertension, diabetes, nephropathy, and retinopathy."	( Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil. Ferrario, C, 2009)	1.31
"Olmesartan medoxomil (OLM) is an antihypertensive angiotensin II receptor blocker. "	( Solubilized formulation of olmesartan medoxomil for enhancing oral bioavailability. Choi, WS; Choi, YB; Choi, YW; Kang, MJ; Kim, HS; Lee, BS; Lee, J; Lee, SK, 2009)	2.09
"Olmesartan medoxomil (OM) is a prodrug type angiotensin II type 1 receptor antagonist widely prescribed as an antihypertensive agent. "	( Human carboxymethylenebutenolidase as a bioactivating hydrolase of olmesartan medoxomil in liver and intestine. Fujimori, I; Ikeda, T; Ishizuka, T; Izumi, T; Kato, M; Kubota, K; Kurihara, A; Noji-Sakikawa, C; Okazaki, O; Saito, M; Yoshigae, Y, 2010)	2.04
"Olmesartan medoxomil is an angiotensin II-receptor antagonist used in the treatment of hypertension. "	( The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study. Hu, BQ; Jiang, Y; Li, KY; Liang, JP; Lin, XP; Luo, CH; Qiu, Y; Yang, N, 2010)	2.03
"Olmesartan medoxomil is an orally administered angiotensin II receptor antagonist, selective for the angiotensin II type 1 receptor, which has established antihypertensive efficacy in adults. "	( Olmesartan medoxomil: in children and adolescents with hypertension. Keating, GM; Muir, VJ, 2010)	3.25
"Olmesartan medoxomil is a new angiotensin II receptor blocker. "	( Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements. Chen, CL; Elliott, WJ; Izzo, J; Masonson, H; Neutel, J, )	1.87
"Olmesartan medoxomil is a competitively priced addition to the class of angiotensin II receptor antagonists. "	( Olmesartan medoxomil: the seventh angiotensin receptor antagonist. Franks, AM; Gardner, SF, 2003)	3.2
"Olmesartan medoxomil is an effective antihypertensive agent, with BP-lowering efficacy at the starting dose similar to that of amlodipine, and is associated with more patients achieving the rigorous BP goals of SBP <130 mmHg and DBP <85 mmHg."	( Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. Chrysant, SG; Marbury, TC; Robinson, TD, 2003)	1.31
"Olmesartan medoxomil is a new angiotensin-II receptor antagonist for the treatment of hypertension. "	( Clinical efficacy of olmesartan medoxomil. Brunner, HR; Laeis, P, 2003)	2.08
"Olmesartan medoxomil is an angiotensin II receptor antagonist that selectively and competitively inhibits the angiotensin II type 1 receptor."	( Clinical efficacy and tolerability of olmesartan. Brunner, HR, 2004)	1.77
"Olmesartan medoxomil is a new angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension. "	( [Pharmacological profiles and clinical effects of olmesartan medoxomil, a novel angiotensin II receptor blocker]. Mizuno, M; Sada, T, 2004)	2.02
"Olmesartan medoxomil is a new orally active angiotensin II (Ang II) type 1 receptor antagonist. "	( Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist. Kohzuki, M; Yoshida, K, 2004)	2.04
"Olmesartan medoxomil (CS-866) is a new orally active angiotensin II receptor antagonist that is highly selective for the AT1 receptor subtype."	( Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients. Gao, Y; Hisaoka, M; Shiga, H; Wada, DR; Yoshihara, K, 2005)	1.99
"Olmesartan medoxomil is an angiotensin II receptor blocker with similar antihypertensive efficacy as the calcium channel blocker amlodipine besylate in patients with mild-to-moderate hypertension. "	( Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. Chrysant, SG; Marbury, TC; Silfani, TN, 2006)	1.99
"Olmesartan medoxomil is an angiotensin II receptor antagonist. "	( Olmesartan medoxomil: current status of its use in monotherapy. Brunner, HR, 2006)	3.22
"Olmesartan medoxomil is a nonpeptide angiotensin II receptor antagonist which selectively and competitively inhibits the type 1 angiotensin II receptor without affecting other receptors regulating the cardiovascular system. "	( Olmesartan medoxomil. Jarvis, B; Warner, GT, 2002)	3.2

Excerpt	Reference	Relevance
"Olmesartan medoxomil has a favorable safety and efficacy profile, with blood pressure-lowering effects comparable to those of other angiotensin receptor blockers (i.e., losartan, valsartan, irbesartan). "	( Olmesartan medoxomil: the seventh angiotensin receptor antagonist. Franks, AM; Gardner, SF, 2003)	3.2
"Olmesartan medoxomil (OM), an ARB, has been well studied and achieves significant BP lowering and goal achievement with good tolerability."	( Efficacy and safety of olmesartan medoxomil in patients with stage 1 hypertension: blood pressure lowering and goal achievement. Wilford Germino, F, 2010)	1.39
"Olmesartan medoxomil has a favorable safety and efficacy profile, with blood pressure-lowering effects comparable to those of other angiotensin receptor blockers (i.e., losartan, valsartan, irbesartan). "	( Olmesartan medoxomil: the seventh angiotensin receptor antagonist. Franks, AM; Gardner, SF, 2003)	3.2
"Olmesartan medoxomil has been reported to be an effective agent for the treatment of hypertension. "	( Olmesartan medoxomil: an angiotensin II-receptor blocker. Brousil, JA; Burke, JM, 2003)	3.2
"Olmesartan medoxomil has minimal adverse effects with no clinically important drug interactions."	( Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist. Kohzuki, M; Yoshida, K, 2004)	1.32
"Olmesartan medoxomil has one of the highest degrees of antihypertensive efficacy among the angiotensin II type 1 receptor antagonists."	( Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence. Miyazaki, M; Takai, S, 2006)	1.46
"Olmesartan medoxomil has shown no clinically important pharmacokinetic interactions with digoxin, warfarin or antacid (aluminium magnesium hydroxide)."	( Olmesartan medoxomil. Jarvis, B; Warner, GT, 2002)	2.48

Excerpt	Reference	Relevance
"Olmesartan medoxomil treatment also reduced left ventricular mass index (p<0.001) and LVH (p<0.001)."	( Effect of olmesartan medoxomil on cystatin C level, left ventricular hypertrophy and diastolic function. Albayrak, S; Alemdar, R; Aydin, M; Kaya, A; Ordu, S; Ozhan, H; Yazici, M, 2009)	1.48
"An olmesartan medoxomil-based treatment algorithm was evaluated in a double-blind, placebo-controlled titration study in 276 patients with stage 1 (47.1%) or 2 (52.9%) hypertension. "	( Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study. Dubiel, R; Kereiakes, DJ; Maa, JF; Shojaee, A, 2010)	1.35
"An olmesartan medoxomil-based treatment algorithm effectively reduced SBP and achieved SBP targets in patients with stage 1 or 2 hypertension. "	( Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study. Dubiel, R; Kereiakes, DJ; Maa, JF; Shojaee, A, 2010)	1.35
"An olmesartan medoxomil ± HCTZ treatment regimen significantly reduced BP from baseline in patients with hypertension and type 2 diabetes."	( Seated cuff blood pressure-lowering efficacy of an olmesartan medoxomil-based treatment regimen in patients with type 2 diabetes mellitus. Kereiakes, DJ; Neutel, JM, 2011)	1.24
"Treatment with olmesartan medoxomil/amlodipine 20 mg/5 mg FDC tablets was safe and well tolerated."	( Pharmacokinetic and pharmacodynamic profiles of a fixed-dose combination of olmesartan medoxomil and amlodipine in healthy Chinese males and females. Chen, X; Hu, P; Jiang, J; Liu, H; Liu, T; Zhao, Q; Zhong, W, 2012)	0.95
"Treatment with olmesartan medoxomil resulted in a significant placebo-adjusted reduction of mean 24-hour ambulatory diastolic blood pressure of 9.6 mm Hg, 12.2 mm Hg, and 10.6 mm Hg in the 5-, 20-, and 80-mg q.d."	( Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, as assessed by ambulatory blood pressure measurements. Chen, CL; Elliott, WJ; Izzo, J; Masonson, H; Neutel, J, )	0.76
"Treatment with olmesartan medoxomil 40 mg/day was associated with a lower frequency of adverse events than olmesartan medoxomil/hydrochlorothiazide combination therapy (21.5% vs 28.3%, respectively)."	( Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Barrios, V; Boccanelli, A; Böhm, M; Ewald, S; Girerd, X; Heagerty, A; Krzesinski, JM; Lins, R; Rodicio, J; Stefenelli, T; Woittiez, A, 2007)	0.97

Excerpt	Reference	Relevance
"Olmesartan medoxomil was safe and highly effective in lowering blood pressure in patients with mild to moderate essential hypertension in these studies."	( Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. Laeis, P; Püchler, K; Stumpe, KO, 2001)	1.75
" During combined treatment with olmesartan plus glibenclamide, no adverse event occurred, and the medications were well tolerated."	( Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. Bolbrinker, J; Huber, M; Kreutz, R, 2006)	0.62
" (4) The incidence of study drug-related adverse events (AEs) in olmesartan group (10."	( [Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension]. Cai, NS; Chen, YZ; Fan, WH; Guo, JX; He, B; Huang, J; Ke, YN; Li, XL; Ma, H; Wu, ZG; Zhu, DL; Zhu, JR, 2006)	0.64
"This study shows that olmesartan medoxomil, at oral dose of 20 mg-40 mg once daily was effective and safe for hypertension treatment and the hypotensive effect was superior to losartan potassium (50 mg-100 mg once daily)."	( [Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension]. Cai, NS; Chen, YZ; Fan, WH; Guo, JX; He, B; Huang, J; Ke, YN; Li, XL; Ma, H; Wu, ZG; Zhu, DL; Zhu, JR, 2006)	0.96
" Based above analysis, it was concluded that olmesartan medoxomil 20 mg was safe and there were no any accumulation in healthy Chinese subjects after multiple-dose."	( Pharmacokinetic and safety profile of olmesartan medoxomil in healthy Chinese subjects after single and multiple administrations. Hu, P; Jiang, J; Liu, D, 2009)	0.88
" After 8 weeks of treatment, the combination of amlodipine + OM is safe and efficacious, irrespective of baseline hypertension stage or prior antihypertensive medication use."	( Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. Karki, S; Lee, J; Melino, M; Oparil, S, 2009)	0.57
" Study medication was safe and well tolerated."	( Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. Chrysant, SG; Heyrman, R; Karki, S; Lee, J; Melino, M; Oparil, S, 2009)	0.57
" The incidence of adverse events was similar in the O/A combination groups and the monotherapy groups."	( A randomized, double-blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT study. Kuramoto, K; Ogihara, T; Saruta, T; Shimada, K, 2009)	0.57
" Adverse events were generally mild and unrelated to study medication."	( A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Bhorat, AE; Hazan, L; Hernández Rodriguez, OA; Heyrman, R; Miyazaki, K; Tao, B, 2010)	0.6
"One of the reasons for suboptimal blood pressure (BP) control in patients with hypertension is poor adherence to treatment, which may be caused by treatment-emergent adverse events."	( Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study. Chrysant, SG, 2010)	0.65
"In patients with stage 1 hypertension, the olmesartan medoxomil-based regimen was generally well tolerated at all titration steps, and discontinuation due to adverse events was similar between olmesartan medoxomil and placebo."	( Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study. Chrysant, SG, 2010)	0.91
" This regimen was also effective in terms of BP lowering and enabling patients to achieve BP goals without an adverse effect on tolerability."	( Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study. Chrysant, SG, 2010)	0.65
" The most common adverse events reported were dizziness (82."	( Olmesartan medoxomil evaluated for safety and efficacy in Indian patients with essential hypertension: a real world observational postmarketing surveillance. Rana, R; Singh, A, 2010)	1.8
" These results suggest that olmesartan/amlodipine is effective and safe in a wide range of patients, regardless of age or hypertension severity."	( Efficacy and safety of olmesartan medoxomil plus amlodipine in age, gender and hypertension severity defined subgroups of hypertensive patients. Böhm, M; Schmieder, RE, 2011)	0.68
" The proportion of patients with drug-related adverse events was comparable in the two groups (3."	( Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. Auteri, A; Malacco, E; Omboni, S; Volpe, M; Zanchetti, A, 2010)	0.63
" Moreover, combination therapy comprising OM plus hydrochlorothiazide can significantly increase BP goal achievement without significantly increasing adverse events."	( Efficacy and safety of olmesartan medoxomil in patients with stage 1 hypertension: blood pressure lowering and goal achievement. Wilford Germino, F, 2010)	0.67
" The proportion of patients with drug-related adverse events was comparable in the two groups (4."	( Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension. Barton, J; Mallion, JM; Narkiewicz, K; Omboni, S; Panzer, PK; Puig, JG; Stefanadis, C; Van Mieghem, W; Zweiker, R, 2011)	0.37
" In conclusion, PIO and OLM combination can primarily be stated as safe in terms of present toxicity and pharmacokinetics findings."	( Development of safety profile evaluating pharmacokinetics, pharmacodynamics and toxicity of a combination of pioglitazone and olmesartan medoxomil in Wistar albino rats. Nandi, U; Pal, TK; Sengupta, P, 2012)	0.59
" Olmesartan and LOS were well tolerated, and the most common treatment-emergent adverse event was headache."	( Efficacy/safety of olmesartan medoxomil versus losartan potassium in patients by stage 1 or 2 hypertension. Chavanu, KJ; Flack, JM; Graff, A; Li, W, 2012)	0.71
" The incidence of drug-related adverse effects did not differ significantly between the groups."	( Efficacy and safety of olmesartan medoxomil/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy. Gao, PJ; Zhang, SY; Zhu, JR, 2014)	0.71
" There were 50 adverse events in 41 patients (22."	( Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: Ahn, Y; Baek, SH; Choi, DH; Hong, TJ; Hyon, MS; Jeong, JO; Kang, WC; Kim, HS; Kim, SH; Kim, YH; Lee, SC; Nam, CW; Park, JS; Park, TH; Seo, HS; Shim, WJ; Shin, JH, 2016)	0.68
" In addition, the olmesartan nanoemulsion was found to be safe and non-toxic, as it neither produced any lethality nor remarkable haematological, biochemical and structural adverse effects as observed during the 28-days sub-chronic toxicity studies in experimental Wistar rats."	( Comparative biodistribution and safety profiling of olmesartan medoxomil oil-in-water oral nanoemulsion. Choudhury, H; Gorain, B; Jaisankar, P; Karan, S; Pal, TK; Tekade, RK, 2016)	0.68
" Treatment-emergent adverse events/serious adverse events occurred in 78."	( Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide. Barger, B; Cushman, WC; Handley, A; Lloyd, E; Neutel, JM, 2017)	0.67
" The therapy was safe and well tolerated."	( Real-World Effectiveness and Safety of a Single-Pill Combination of Olmesartan/Amlodipine/Hydrochlorothiazide in Korean Patients with Hypertension and Cardiovascular Risk Factors. Hong, JH; Hyun, D; Kim, GH; Kim, HL; Kim, W; Lim, S; Min, KW; Oh, J; Park, SD; Shin, J, 2023)	0.91

Excerpt	Reference	Relevance
"8 hours, and the terminal elimination half-life ranged from 12 to 18 hours."	( Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. Masonson, HN; Schwocho, LR, 2001)	0.31
" Pharmacokinetic steady state was reached within the first few days after oral dosing."	( Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. Gonzalez, L; Laeis, P; Püchler, K; Schwocho, LR; Sudhop, T; von Bergmann, K, 2001)	1.75
"To develop a population pharmacokinetic model for olmesartan (RNH-6270), the active metabolite of olmesartan medoxomil, in healthy volunteers and hypertensive patients, and to evaluate effects of covariates on the apparent oral clearance (CL/F), with particular emphasis on the effect of race."	( Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients. Gao, Y; Hisaoka, M; Shiga, H; Wada, DR; Yoshihara, K, 2005)	0.77
"The pharmacokinetic data of olmesartan were well described by a two-compartment linear model with first-order absorption and an absorption lag-time, parameterised in terms of CL/F (6."	( Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients. Gao, Y; Hisaoka, M; Shiga, H; Wada, DR; Yoshihara, K, 2005)	0.55
"The population pharmacokinetic analysis of olmesartan showed that: (i) severe renal impairment (serum creatinine >265 micromol/L [approximately 3 mg/dL]) could cause a clearance decrease of > or =30%; (ii) older age, lower bodyweight and being female were determinants of lower clearance but their effects on olmesartan clearance were within 20%; (iii) no statistically significant difference in clearance was found between Westerners and Japanese."	( Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients. Gao, Y; Hisaoka, M; Shiga, H; Wada, DR; Yoshihara, K, 2005)	0.55
"To investigate the pharmacokinetic interactions, safety, and tolerability of the combination of olmesartan medoxomil with glibenclamide."	( Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. Bolbrinker, J; Huber, M; Kreutz, R, 2006)	0.84
"With the exception of a slight shift of tmax values for glibenclamide, the concomitant administration of olmesartan medoxomil with glibenclamide had no significant effects on the steady-state pharmacokinetics of either agent."	( Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. Bolbrinker, J; Huber, M; Kreutz, R, 2006)	0.83
" This trial investigated the possibility of pharmacokinetic interactions between the AT1 receptor antagonist olmesartan medoxomil and the thiazide diuretic hydrochlorothiazide in healthy subjects."	( Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects. Bolbrinker, J; Huber, M; Kreutz, R, 2006)	0.87
" The primary pharmacokinetic parameters evaluated were: the area under the plasma concentration versus time curve at steady state (AUCss,tau), the maximum plasma concentration at steady state (Css,max), and the time at which Css,max occurred (tmax)."	( Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects. Bolbrinker, J; Huber, M; Kreutz, R, 2006)	0.66
"Complete data sets from 17 subjects were available for pharmacokinetic analyses."	( Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects. Bolbrinker, J; Huber, M; Kreutz, R, 2006)	0.66
"These results show that there is little or no potential for a clinically relevant pharmacokinetic interaction between olmesartan medoxomil 20 mg and hydrochlorothiazide 25 mg, and therefore dosage adjustment should not be necessary when they are co-administered."	( Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects. Bolbrinker, J; Huber, M; Kreutz, R, 2006)	0.87
"Population pharmacokinetic models for amlodipine and olmesartan were developed using data collected from 4 phase I studies in healthy volunteers and 1 phase III study in subjects with mild to severe hypertension."	( Evaluation of population pharmacokinetics and exposure-response relationship with coadministration of amlodipine besylate and olmesartan medoxomil. Carrothers, TJ; Khariton, T; Kshirsagar, S; Lee, J; Rohatagi, S; Salazar, D, 2008)	0.55
" Another pharmacokinetic parameter, such as maximum plasma drug concentration (C (max)), biological half-life (t (1/2)) and time to reach C (max) (t (max)), were almost similar in both groups."	( Pharmacokinetics of olmesartan medoxomil in hemodialysis patients: little effect of dialysis upon its pharmacokinetics. Hamano, T; Horio, M; Imai, E; Isaka, Y; Ito, T; Iwatani, H; Kawada, N; Matsui, I; Nagasawa, Y; Tanaka, H, 2009)	0.68
"The impact of SLCO1B1 polymorphism on the pharmacokinetics of olmesartan and on the pharmacokinetic interaction between pravastatin and olmesartan was investigated."	( Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism. Higuchi, S; Hirota, T; Ieiri, I; Irie, S; Kawabata, K; Kimura, M; Kusuhara, H; Sugiyama, Y; Suwannakul, S, 2008)	0.35
" From a pharmacokinetic perspective, the 2 drugs are well suited to coadministration in a fixed-dose combination."	( Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination. Allison, M; Bathala, MS; Haworth, S; Heyrman, R; Lee, J; Noveck, R; Rohatagi, S; Rubets, I; Salazar, DE; Shenouda, M, 2008)	0.57
" Blood and urine samples were obtained for a 48-h pharmacokinetic evaluation on two PK days (Day 1 and Day 9)."	( Pharmacokinetic and safety profile of olmesartan medoxomil in healthy Chinese subjects after single and multiple administrations. Hu, P; Jiang, J; Liu, D, 2009)	0.62
" Bioequivalence was established for all pharmacokinetic parameters."	( Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. Bolbrinker, J; Huber, M; Kreutz, R; Scholze, J, 2009)	0.64
" In conclusion, the effects of olmesartan medoxomil and azelnidipine were modestly correlated with pharmacokinetic profiles, and the pre-treatment PRA level could be a useful determinant of responsiveness in selecting olmesartan medoxomil and azelnidipine."	( Comparative pharmacodynamics of olmesartan and azelnidipine in patients with hypertension: a population pharmacokinetic/pharmacodynamic analysis. Arakawa, K; Kuramoto, K; Tanigawara, Y; Yoshihara, K, 2009)	0.64
" The pharmacokinetic parameters of IIa were studied and compared with those of olmesartan medoxomil."	( Novel amides and esters prodrugs of olmesartan: Synthesis, bioconversion, and pharmacokinetic evaluation. Chang, JS; Cho, YJ; Choi, WK; Choi, YW; Chung, HJ; El-Gamal, MI; Jeon, HR; Kim, HI; Lee, BS; Lee, J; Lee, WS; Lee, YS; Oh, CH; Park, JH, 2010)	0.59
"This study investigated the relative bioavailability and fasting pharmacokinetic properties of olmesartan after single doses of a 20-mg test tablet, a 20-mg test capsule, and a commercially available 20-mg reference tablet in healthy Chinese male volunteers."	( The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study. Hu, BQ; Jiang, Y; Li, KY; Liang, JP; Lin, XP; Luo, CH; Qiu, Y; Yang, N, 2010)	0.59
" And the pharmacokinetic parameters for olmesartan after their oral administration were also estimated and compared with those in case of olmesartan medoxomil."	( Design, synthesis, bioconversion, and pharmacokinetics evaluation of new ester prodrugs of olmesartan. Anbar, HS; Chang, JS; Cho, YJ; Choi, YW; Chung, HJ; El-Gamal, MI; Jeon, HR; Kim, HI; Lee, BS; Lee, DJ; Lee, J; Lee, SA; Lee, WS; Moon, JY; Oh, CH, 2011)	0.57
" Pharmacokinetic study was performed by orally administering PIO and OLM at single dose of 3 and 2mg/kg, respectively alone and in combination analyzing the plasma samples using LC-MS/MS."	( Development of safety profile evaluating pharmacokinetics, pharmacodynamics and toxicity of a combination of pioglitazone and olmesartan medoxomil in Wistar albino rats. Nandi, U; Pal, TK; Sengupta, P, 2012)	0.59
" Plasma elimination half-life and time to maximum plasma concentration were similar across the three groups."	( Pharmacokinetics of olmesartan medoxomil in pediatric patients with hypertension. Blowey, DL; Blumer, J; Heyrman, R; Rohatagi, S; Salazar, DE; Sherbotie, JR; Song, S; Sullivan, JE; Wells, TG, 2012)	0.7
"Olmesartan medoxomil was well tolerated and demonstrated a pharmacokinetic profile in pediatric patients similar to that of adults when adjusted for body size."	( Pharmacokinetics of olmesartan medoxomil in pediatric patients with hypertension. Blowey, DL; Blumer, J; Heyrman, R; Rohatagi, S; Salazar, DE; Sherbotie, JR; Song, S; Sullivan, JE; Wells, TG, 2012)	2.15
" Meanwhile, blood pressure and heart rate were repeatedly taken to delineate the pharmacodynamic profiles."	( Pharmacokinetic and pharmacodynamic profiles of a fixed-dose combination of olmesartan medoxomil and amlodipine in healthy Chinese males and females. Chen, X; Hu, P; Jiang, J; Liu, H; Liu, T; Zhao, Q; Zhong, W, 2012)	0.61
" The elimination half-life of amlodipine is more than twice as long as that of olmesartan."	( Pharmacokinetic and pharmacodynamic profiles of a fixed-dose combination of olmesartan medoxomil and amlodipine in healthy Chinese males and females. Chen, X; Hu, P; Jiang, J; Liu, H; Liu, T; Zhao, Q; Zhong, W, 2012)	0.61
"After single and multiple doses of olmesartan medoxomil/amlodipine 20 mg/5 mg FDC tablets the pharmacokinetic profiles of olmesartan or amlodipine were comparable to those reported for monotherapy with olmesartan medoxomil or amlodipine, except that the elimination half-life of olmesartan was longer because of the longer time course over which pharmacokinetic blood sampling was carried out in this study."	( Pharmacokinetic and pharmacodynamic profiles of a fixed-dose combination of olmesartan medoxomil and amlodipine in healthy Chinese males and females. Chen, X; Hu, P; Jiang, J; Liu, H; Liu, T; Zhao, Q; Zhong, W, 2012)	0.89
" For the colesevelam coadministration periods, 3,750 mg once daily was dosed throughout the pharmacokinetic sampling period."	( The effects of colesevelam HCl on the single-dose pharmacokinetics of glimepiride, extended-release glipizide, and olmesartan medoxomil. He, L; Lee, J; Mendell-Harary, J; Tao, B; Walker, J; Wickremasingha, P; Wight, D, 2014)	0.61
" The pharmacokinetic parameters were calculated, and the 90% confidence intervals (CIs) of the geometric mean ratio (test/reference) of the parameters were obtained by analysis of variance (ANOVA) on logarithmically transformed data."	( Pharmacokinetic properties and bioequivalence of olmesartan medoxomil/hydrochlorothiazide in healthy Korean male subjects. Chae, SW; Choi, Y; Im, YJ; Jeon, JY; Jin, C; Jung, JA; Kim, MG; Kim, Y; Park, K, 2014)	0.66
"The objective of the present study was to develop population pharmacokinetic models for olmesartan medoxomil and hydrochlorothiazide and to investigate the influence of demographic factors on these population pharmacokinetics."	( Development of a population pharmacokinetic model to describe olmesartan medoxomil/ hydrochlorothiazide (20/12.5 mg) FDC tablet in male healthy South Korean subjects. Back, HM; Baek, IH; Chae, JW; Jung, SH; Kang, W; Kwon, KI; Lee, BY; Seo, JW; Song, BJ; Yun, HY, 2014)	0.87
" All evaluations indicated that the pharmacokinetic profiles of olmesartan medoxomil and hydrochlorothiazide were adequately described using our PPK model."	( Development of a population pharmacokinetic model to describe olmesartan medoxomil/ hydrochlorothiazide (20/12.5 mg) FDC tablet in male healthy South Korean subjects. Back, HM; Baek, IH; Chae, JW; Jung, SH; Kang, W; Kwon, KI; Lee, BY; Seo, JW; Song, BJ; Yun, HY, 2014)	0.88
" The optimized formulation was further evaluated for in vitro drug release, confocal microscopy and in vivo pharmacokinetic study."	( Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment. Ahad, A; Ali, A; Aqil, M; Imam, SS; Kamran, M; Sultana, Y, 2016)	0.66
"The aim of the study was to establish a population pharmacokinetic model for olmesartan, the active metabolite of olmesartan medoxomil, in Indian hypertensive patients, and to evaluate effects of covariates on the volume of distribution (V/F) and oral clearance (CL/F) of olmesartan."	( Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension. Kodati, D; Kotakonda, HK; Yellu, N, 2017)	0.9
" The pharmacokinetic data of olmesartan was well described by a two-compartment linear pharmacokinetic model with first-order absorption and an absorption lag-time."	( Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension. Kodati, D; Kotakonda, HK; Yellu, N, 2017)	0.68
"The final population pharmacokinetic model was demonstrated to be appropriate and effective and it can be used to assess the pharmacokinetic parameters of olmesartan in Indian patients with hypertension."	( Population Pharmacokinetic Modeling of Olmesartan, the Active Metabolite of Olmesartan Medoxomil, in Patients with Hypertension. Kodati, D; Kotakonda, HK; Yellu, N, 2017)	0.68
" Prepared SLNs were evaluated for physical characters and in vivo pharmacokinetic (PK) performance in rats."	( Development of olmesartan medoxomil lipid-based nanoparticles and nanosuspension: preparation, characterization and comparative pharmacokinetic evaluation. B, A; D, N; Veerabrahma, K, 2018)	0.83
" The pharmacokinetic and pharmacodynamic studies of selected formula compared to oral and nasal OLM suspensions were conducted."	( Chitosan nanoparticles for intranasal delivery of olmesartan medoxomil: Pharmacokinetic and pharmacodynamic perspectives. El-Din, SB; Gad, HA; Hassan, RH; Ishak, RAH; Shaker, DS, 2022)	0.97

Excerpt	Reference	Relevance
"Microdialysis combined with tandem mass spectrometry was used to monitor the rapid hydrolysis of CS-866, a new prodrug-type angiotensin II receptor antagonist, in vitro in rat and human plasma as well as in hepatic and intestinal preparations."	( Real-time monitoring of metabolic reactions by microdialysis in combination with tandem mass spectrometry: hydrolysis of CS-866 in vitro in human and rat plasma, livers, and small intestines. Fujimori, I; Ikeda, T; Kobayashi, N; Watanabe, M, 2000)	0.31
" In this randomized double-blind study we investigated renin-angiotensin system blockade obtained with 3 doses of olmesartan medoxomil (20, 40, and 80 mg every day) in 30 normal subjects and compared it with that obtained with lisinopril alone (20 mg every day) or combined with olmesartan medoxomil (20 or 40 mg)."	( Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. Brunner, HR; Burnier, M; Forclaz, A; Hasler, C; Maillard, M; Nussberger, J, 2005)	0.54
"7 ng h/ml in combination with glibenclamide; the corresponding Css,max values were 479."	( Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. Bolbrinker, J; Huber, M; Kreutz, R, 2006)	0.62
" When using combination therapy, antihypertensive agents with complementary mechanisms of action are recommended, for example, an angiotensin receptor blocker (ARB) in combination with hydrochlorothiazide (HCTZ), a beta-blocker + HCTZ, an ACE inhibitor + HCTZ, or a calcium channel blocker + an ACE inhibitor."	( Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension. Greathouse, M, 2006)	1.78
" Patients were given OLM alone or in combination with other antihypertensive drugs at the discretion of the investigators."	( The use of olmesartan medoxomil as monotherapy or in combination with other antihypertensive agents in elderly hypertensive patients in Japan. Hiramatsu, K; Hirata, K; Kobayashi, F; Komiya, M; Kushiro, T; Sagawa, K; Saito, I; Sato, Y, 2008)	0.74
"These results suggest that olmesartan medoxomil combined with amlodipine is effective and well tolerated in reducing BP in patients with moderate to severe hypertension."	( Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Brommer, P; Haag, U; Miele, C; Volpe, M, 2009)	0.94
" Additionally, the increased efficacy resulting from the combination with hydrochlorothiazide does not appear to significantly affect the tolerability profile of olmesartan medoxomil."	( Efficacy and safety of olmesartan medoxomil alone and in combination with hydrochlorothiazide. Punzi, HA, 2009)	0.86
" Although angiotensin receptor blockers (ARBs) may be combined with other anti-hypertensives, it is unclear how the effects of ARBs are influenced by co-administered anti-hypertensives."	( Blood pressure-lowering effects of angiotensin receptor antagonist monotherapy and in combination with other anti-hypertensive drugs in primary care settings in Japan. Hiramatsu, K; Hirata, K; Ishikawa, M; Komiya, M; Kushiro, T; Matsushita, Y; Sagawa, K; Saito, I; Yamashita, T, 2009)	0.35
" We analysed pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in two separate studies."	( Pharmacokinetics and safety of olmesartan medoxomil in combination with either amlodipine or atenolol compared to respective monotherapies in healthy subjects. Bolbrinker, J; Huber, M; Kreutz, R; Scholze, J, 2009)	0.9
"Aliskiren combined with olmesartan reduces proteinuria in CKD patients."	( Beneficial effect of aliskiren combined with olmesartan in reducing urinary protein excretion in patients with chronic kidney disease. Itabashi, M; Kojima, C; Moriyama, T; Nitta, K; Ogawa, T; Sugiura, H; Takei, T; Tsuchiya, K; Tsuruta, Y; Uchida, K, 2012)	0.38
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."	( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012)	0.38
"The study is to investigate drug-drug interaction (DDI) between olmesartan medoxomil and hydrochlorothiazide (HCTZ), to confirm bioequivalence (BE) of a new combined formulation and coadministration of separate local tablets, and to receive pharmacokinetics and tolerability of the new combined formulation after multiple doses in healthy Chinese subjects."	( Pharmacokinetics and tolerability of olmesartan medoxomil plus hydrochlorothiazide combination in healthy Chinese subjects: drug-drug interaction, bioequivalence, and accumulation. Hu, P; Jiang, J; Liu, DY; Wang, CG; Zhang, JY, 2014)	0.91
"Ischemic stroke combined with hypertension can increase risks of stroke recurrence and death."	( The Clinical Efficacy of Clopidogrel Bisulfate Tablets Combined with Olmesartan Medoxomil for Ischemic Stroke with Hypertension and the Effect of Angiotensin II Type 1 Receptor Level on Prognosis. Fang, W; Guo, X; Jiang, H; Jin, X; Liu, Y; Sun, P; Yu, J, 2021)	0.86
"Clopidogrel bisulfate tablets combined with olmesartan medoxomil has prominent clinical effects in the treatment of ischemic stroke patients with hypertension, evidently improving the prognosis."	( The Clinical Efficacy of Clopidogrel Bisulfate Tablets Combined with Olmesartan Medoxomil for Ischemic Stroke with Hypertension and the Effect of Angiotensin II Type 1 Receptor Level on Prognosis. Fang, W; Guo, X; Jiang, H; Jin, X; Liu, Y; Sun, P; Yu, J, 2021)	1.12
"This is a prospective parallel, randomized, double-blind, placebo-controlled trial to study the effects of α lipoic acid in combination with olmesartan medoxomil on blood glucose and oxidation indicators in patients with DN."	( Effects of α lipoic acid combined with olmesartan medoxomil on blood glucose and oxidation indicators in patients with diabetic nephropathy: A protocol for a parallel, randomized, double-blind, controlled clinical trial. Chang, X; Dong, Y; Jiao, S; Li, H; Wu, Y, 2022)	1.19
"This study will evaluate the effects of α lipoic acid combined with olmesartan medoxomil on blood glucose and oxidation indicators in patients with DN."	( Effects of α lipoic acid combined with olmesartan medoxomil on blood glucose and oxidation indicators in patients with diabetic nephropathy: A protocol for a parallel, randomized, double-blind, controlled clinical trial. Chang, X; Dong, Y; Jiao, S; Li, H; Wu, Y, 2022)	1.23
" The availability of OM combined with HCTZ, AML or both at different dosages makes it a valuable option to customize therapy based on the levels of BP and the clinical characteristics of hypertensive patients."	( Single-Pill Combination with Three Antihypertensive Agents to Improve Blood Pressure Control in Hypertension: Focus on Olmesartan-Based Combinations. Burnier, M; Redon, J; Volpe, M, 2023)	0.91

Excerpt	Reference	Relevance
" Absolute bioavailability of RNH-6270 after oral administration of CS-866 was 26%."	( Pharmacokinetics of CS-866, a new angiotensin II receptor blocker, in healthy subjects. Masonson, HN; Schwocho, LR, 2001)	0.31
" Bioavailability (Cmax and area under the curve) increased approximately in proportion with dose, after single and multiple daily oral doses, over the therapeutic dose range (up to 40-80 mg daily), above which systemic availability of olmesartan increased less than proportionally with increase in dose."	( The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. Kirch, W; Laeis, P; Püchler, K, 2001)	0.57
" After single oral doses of 10 mg olmesartan medoxomil daily to patients with mild (Child-Pugh score < or = 6) and moderate (score 7-9) hepatic impairment, Cmax was generally similar to that in healthy matched subjects, but AUC increased by 30 and 48%, respectively, and was reflected in small increases in absolute bioavailability values compared with healthy subject controls."	( Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. Gonzalez, L; Laeis, P; Püchler, K; Schwocho, LR; Sudhop, T; von Bergmann, K, 2001)	2.03
" The absolute bioavailability of olmesartan from olmesartan medoxomil tablets is 28."	( The new oral angiotensin II antagonist olmesartan medoxomil: a concise overview. Brunner, HR, 2002)	0.84
"66 L/h for a typical male Western hypertensive patient), absorption rate constant (1."	( Population pharmacokinetics of olmesartan following oral administration of its prodrug, olmesartan medoxomil: in healthy volunteers and hypertensive patients. Gao, Y; Hisaoka, M; Shiga, H; Wada, DR; Yoshihara, K, 2005)	0.55
" OLM has a low bioavailability (BA), approximately 26% in humans, due to its low water solubility and efflux by drug resistance pumps in the gastrointestinal tract."	( Solubilized formulation of olmesartan medoxomil for enhancing oral bioavailability. Choi, WS; Choi, YB; Choi, YW; Kang, MJ; Kim, HS; Lee, BS; Lee, J; Lee, SK, 2009)	0.65
" These findings may explain the known interaction of telmisartan with digoxin and suggest that it may modulate the bioavailability of drugs whose absorption is restricted by P-gp and possibly also by BCRP or MRP2."	( Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Benndorf, RA; Böger, RH; Divac, N; Haefeli, WE; Herzog, M; Sauer, A; Schwedhelm, E; Weiss, J, 2010)	0.36
"This study investigated the relative bioavailability and fasting pharmacokinetic properties of olmesartan after single doses of a 20-mg test tablet, a 20-mg test capsule, and a commercially available 20-mg reference tablet in healthy Chinese male volunteers."	( The relative bioavailability and fasting pharmacokinetics of three formulations of olmesartan medoxomil 20-mg capsules and tablets in healthy Chinese male volunteers: An open-label, randomized-sequence, single-dose, three-way crossover study. Hu, BQ; Jiang, Y; Li, KY; Liang, JP; Lin, XP; Luo, CH; Qiu, Y; Yang, N, 2010)	0.59
" Reduced nitric oxide (NO) bioavailability has an important role in the process of endothelial dysfunction and hypertension."	( Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil. Mason, RP, 2011)	0.59
" Higher bioavailability compared to commercial oral tablets with a more sustainment behavior was achieved."	( Development and characterization of colloidal soft nano-carriers for transdermal delivery and bioavailability enhancement of an angiotensin II receptor blocker. Elshafeey, AH; Hathout, RM, 2012)	0.38
" To increase oral bioavailability of carboxylic acid 9, two different prodrug approaches were applied."	( Synthesis and pharmacological properties of a new hydrophilic and orally bioavailable 5-HT4 antagonist. Andressen, KW; Brudeli, B; Klaveness, J; Levy, FO; Moltzau, LR; Nguyen, CH; Nilsen, NO, 2013)	0.39
" By analysing the findings of the present investigations based on stability study, Caco-2 permeability, pharmacokinetic profile and pharmacodynamic evaluation indicated that the nanoemulsion of OM (OMF6) could significantly enhance the oral bioavailability of relatively insoluble OM contributing to improved clinical application."	( Nanoemulsion strategy for olmesartan medoxomil improves oral absorption and extended antihypertensive activity in hypertensive rats. Choudhury, H; Gorain, B; Jaisankar, P; Karmakar, S; Kundu, A; Pal, TK; Sarkar, L, 2014)	0.7
"The current research work explores the potential applications of cationic self-nanoemulsifying oily formulations (CSNEOFs) for enhancing the oral bioavailability of olmesartan medoxomil."	( Positively charged self-nanoemulsifying oily formulations of olmesartan medoxomil: Systematic development, in vitro, ex vivo and in vivo evaluation. Beg, S; Jain, S; Katare, OP; Sharma, G; Singh, B; Thanki, K, 2015)	0.85
"15 times improvement in bioavailability of olmesartan with respect to the control formulation in Wistar rats."	( Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment. Ahad, A; Ali, A; Aqil, M; Imam, SS; Kamran, M; Sultana, Y, 2016)	0.66
"Poor aqueous solubility and unfavourable de-esterification of olmesartan medoxomil (a selective angiotensin II receptor blocker), results in low oral bioavailability of less than 26%."	( Comparative biodistribution and safety profiling of olmesartan medoxomil oil-in-water oral nanoemulsion. Choudhury, H; Gorain, B; Jaisankar, P; Karan, S; Pal, TK; Tekade, RK, 2016)	0.93
"Olmesartan medoxomil (OLM) is an antihypertensive drug with low oral bioavailability (28%) resulting from poor aqueous solubility, presystemic metabolism and P-glycoprotein mediated efflux."	( Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation. Chella, N; Kulhari, H; Nooli, M; Shastri, NR; Sistla, R, 2017)	2.14
"32-fold enhancement in relative bioavailability of drug from SLN when compared to that of OLM plain drug on oral administration."	( Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation. Chella, N; Kulhari, H; Nooli, M; Shastri, NR; Sistla, R, 2017)	0.7
"The aim of the present study is to increase the saturation solubility and oral bioavailability of olmesartan medoxomil (OLM) using nano-sized crystals produced using a combination of antisolvent precipitation and high-shear homogenization."	( Formulation, optimization, and in vitro-in vivo evaluation of olmesartan medoxomil nanocrystals. Arora, S; Dora, CP; Jain, S; Patel, K; Reddy, VA, 2017)	0.91
"The aim of the present investigation was to enhance the oral bioavailability of olmesartan medoxomil by improving its solubility and dissolution rate by preparing nanosuspension (OM-NS), using the Box-Behnken design."	( Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability. Kishan, V; Nagaraj, K; Narendar, D, 2017)	1.04
"The current study explores the potential of nanostructured lipid carriers (NLCs) for oral bioavailability enhancement of olmesartan medoxomil (OLM) by systemic design approach."	( Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability. Dora, CP; Jain, S; Kaithwas, V; Kushwah, V, 2017)	0.94
"The aim was to enhance the oral bioavailability of olmesartan medoxomil (OM) by preparing solid lipid nanoparticles (SLNs) and comparing with nanosuspension (OM-NS)."	( Development of olmesartan medoxomil lipid-based nanoparticles and nanosuspension: preparation, characterization and comparative pharmacokinetic evaluation. B, A; D, N; Veerabrahma, K, 2018)	1.09
"Olmesartan medoxomil (OLM) is an antihypertensive drug with low oral bioavailability due to extensive first-pass metabolism."	( Use of transethosomes for enhancing the transdermal delivery of olmesartan medoxomil: in vitro, ex vivo, and in vivo evaluation. Abdelbary, AA; Albash, R; El-Nabarawi, MA; Refai, H, 2019)	2.2
"Olmesartan medoxomil (OM) is a hydrophobic antihypertensive drug with low bioavailability (26%) and is known to have adverse effects such as celiac disease and enteropathy."	( Design and development of a self-microemulsifying drug delivery system of olmesartan medoxomil for enhanced bioavailability. Burak Ozkaya, A; Karasulu, E; Kirilmaz, L; Komesli, Y; Ugur Ergur, B, 2019)	2.19
"The aim of the study was to improve the oral bioavailability of poorly water-soluble olmesartan medoxomil (OLM) by using different particle size-reduction strategies."	( In Vitro and In Vivo Evaluation of Olmesartan Medoxomil Microcrysta ls and Nanocrystals: Preparation, Characterization, and Pharmacokinet ic Comparison in Beagle Dogs. Chai, R; Fu, Q; Gao, H; Guo, M; He, Z; Liu, H; Ma, Z, 2019)	1.01
" In contrast, OLM microcrystals failed to improve the oral bioavailability of the drugs."	( In Vitro and In Vivo Evaluation of Olmesartan Medoxomil Microcrysta ls and Nanocrystals: Preparation, Characterization, and Pharmacokinet ic Comparison in Beagle Dogs. Chai, R; Fu, Q; Gao, H; Guo, M; He, Z; Liu, H; Ma, Z, 2019)	0.79
"Particles size reduction to nano-scale by means of nanocrystals technology significantly increased in vitro dissolution rate and in vivo oral bioavailability of OLM."	( In Vitro and In Vivo Evaluation of Olmesartan Medoxomil Microcrysta ls and Nanocrystals: Preparation, Characterization, and Pharmacokinet ic Comparison in Beagle Dogs. Chai, R; Fu, Q; Gao, H; Guo, M; He, Z; Liu, H; Ma, Z, 2019)	0.79
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51
"The intention of this work was to load olmesartan medoxomil (OLM), a sparsely water soluble antihypertensive bioactive with low oral bioavailability (26%), into PEGylated bilosomes (PBs) for augmenting its transdermal delivery."	( Tailoring of PEGylated bilosomes for promoting the transdermal delivery of olmesartan medoxomil: in-vitro characterization, ex-vivo permeation and in-vivo assessment. Abdelbary, AA; Albash, R; El-Nabarawi, MA; Refai, H, 2019)	1.01
"Olmesartan medoxomil (OLM) an antihypertensive molecule with poor solubility and poor bioavailability (26% when taken orally) was selected as a model drug."	( Bioavailability Enhancement of Olmesartan Medoxomil Using Hot-Melt Extrusion: In-Silico, In-Vitro, and In-Vivo Evaluation. Deshpande, V; Gokarna, V; Jadhav, P; Vavia, P, 2020)	2.29
" However, poor water solubility and low bioavailability limit its widespread use."	( Preparation of olmesartan medoxomil solid dispersion with sustained release performance by mechanochemical technology. Dushkin, AV; Feng, Z; Ren, W; Su, W; Zhang, Q; Zhao, Y, 2022)	1.07
"Nasal drug delivery has the potential to improve the systemic bioavailability of drugs with low oral bioavailability."	( Chitosan nanoparticles for intranasal delivery of olmesartan medoxomil: Pharmacokinetic and pharmacodynamic perspectives. El-Din, SB; Gad, HA; Hassan, RH; Ishak, RAH; Shaker, DS, 2022)	0.97
"This study aims to formulate Olmesartan medoxomil (OM) into oral fast-dissolving tablets (FDTs) to improve its solubility and bioavailability via two different techniques; The polymer-based surface solid dispersion (SSD) technique and the solidified surfactant (SS) technique."	( Dissolution enhancement of olmesartan medoxomil through polymer-based surface solid dispersion and solidified surfactant techniques. Al-Mahallawi, AM; Daihom, BA; Elbortokaly, HM; Mohamed, MI, 2022)	1.31

Excerpt	Relevance	Reference
"This study was conducted to assess the dose-response relationship of the new angiotensin II (Ang II) antagonist CS-866 on blood pressure and on endocrine parameters in hypertensive patients with an activated renin-angiotensin system."	( Blood pressure and endocrine effects of single doses of CS-866, a novel angiotensin II antagonist, in salt-restricted hypertensive patients. Brunner, HR; Laeis, P; Nussberger, J; Püchler, K; Witte, PU, 1997)	0.3
" Such pharmacological studies can be used to investigate dose-response relationships."	( Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist. Brunner, HR; Nussberger, J, 2001)	0.31
" Since the increased plasma concentrations (Cmax and AUC(0-24 h)) in elderly and very elderly patients, and in mild and moderate renal and hepatic impairment, were several-fold lower than plasma concentrations observed in other studies after 80 mg olmesartan medoxomil daily that were well tolerated, a dosing adjustment in these groups is not considered necessary."	( Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. Gonzalez, L; Laeis, P; Püchler, K; Schwocho, LR; Sudhop, T; von Bergmann, K, 2001)	1.93
"All studies used conventional sphygmomanometry for blood pressure measurements at trough (end of the dosing interval)."	( Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. Laeis, P; Püchler, K; Stumpe, KO, 2001)	0.31
"This review describes the mechanism of action, pharmacokinetics, adverse-effect profile, drug-interaction potential, and dosing of olmesartan medoxomil."	( Olmesartan medoxomil: an angiotensin II-receptor blocker. Brousil, JA; Burke, JM, 2003)	1.97
" It then outlines the clinical pharmacokinetics and interaction profile of the novel antihypertensive olmesartan medoxomil, an angiotensin II receptor antagonist (AIIRA), and relates the findings to the recommended dosing regimen and tolerability of the drug."	( Can the pharmacokinetic characteristics of olmesartan medoxomil contribute to the improvement of blood pressure control? Wehling, M, 2004)	0.8
" Dosage was doubled at week 4 and hydrochlorothiazide was added at week 12 if blood pressure response was inadequate."	( Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. Stumpe, KO, 2004)	0.32
" The recommended usual dosage is 20 mg/day."	( [The drug of the month: Olmesartan medoxomil]. Krzesinski, JM; Scheen, AJ, 2004)	0.63
" Twenty-four-hour ambulatory blood pressure monitoring (ABPM) allows accurate assessment of a patient's hypertension and risk for cardiovascular events, and provides the most accurate measure of an antihypertensive agent's efficacy throughout a 24-hour dosing interval."	( Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Dubiel, R; Jones, M; Smith, DH, 2005)	0.54
"The combination of olmesartan with glibenclamide did not influence the bioequivalence of the area under the plasma-concentration time curve at steady state during one dosing interval 0 to tau = 24 hours (AUCss,tau) or the maximum steady-state concentration (Css,max) of both substances."	( Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. Bolbrinker, J; Huber, M; Kreutz, R, 2006)	0.62
"These results show that there is little or no potential for a clinically relevant pharmacokinetic interaction between olmesartan medoxomil 20 mg and hydrochlorothiazide 25 mg, and therefore dosage adjustment should not be necessary when they are co-administered."	( Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects. Bolbrinker, J; Huber, M; Kreutz, R, 2006)	0.87
" If the subject's seating diastolic blood pressure (SeDBP) was still >or=90 mm Hg, the dosage was doubled for another 4 weeks; for those subjects whose SeDBP was <90 mm Hg after 4-week treatment, the initial dosage remained unchanged and the treatment continued until completion of the study."	( [Efficacy and safety of olmesartan medoxomil versus losartan potassium in Chinese patients with mild to moderate essential hypertension]. Cai, NS; Chen, YZ; Fan, WH; Guo, JX; He, B; Huang, J; Ke, YN; Li, XL; Ma, H; Wu, ZG; Zhu, DL; Zhu, JR, 2006)	0.64
"A simple, rapid and reliable UV spectrophotometric method was developed for the determination of olmesartan medoxomil in pharmaceutical dosage forms."	( Determination of olmesartan medoxomil in tablets by UV-Vis spectrophotometry. Altinoz, S; Celebier, M, 2007)	0.9
" This article addresses this issue by reviewing the dose-response characteristics of olmesartan medoxomil and other ARBs, as well as the relationship between ARB uptitration and BP goal attainment."	( Dose-response characteristics of olmesartan medoxomil and other angiotensin receptor antagonists. Smith, DH, 2007)	0.84
" Notably, BP control is sustained throughout the 24-hour dosage interval, including during the last 4 hours of this period."	( Olmesartan medoxomil: a review of its use in the management of hypertension. McCormack, PL; Scott, LJ, 2008)	1.79
"The pharmacokinetics of amlodipine and olmesartan in healthy volunteers after coadministration of amlodipine besylate and olmesartan medoxomil concomitantly as separate dosage forms and together in a fixed-dose combination tablet were characterized in 5 phase I, randomized, crossover studies."	( Pharmacokinetics of amlodipine and olmesartan after administration of amlodipine besylate and olmesartan medoxomil in separate dosage forms and as a fixed-dose combination. Allison, M; Bathala, MS; Haworth, S; Heyrman, R; Lee, J; Noveck, R; Rohatagi, S; Rubets, I; Salazar, DE; Shenouda, M, 2008)	0.77
" black triangle In the comparison with amlodipine monotherapy, >70% of olmesartan medoxomil/amlodipine recipients, some requiring upwards dosage adjustment, met BP goals."	( Olmesartan medoxomil/amlodipine. Keam, SJ; Sanford, M, 2009)	2.03
" An OM-based treatment algorithm effectively lowers BP in an elderly patient population throughout the 24-hour dosing interval without compromising tolerability."	( The effects of an olmesartan medoxomil-based treatment algorithm on 24-hour blood pressure levels in elderly patients aged 65 and older. Dubiel, R; Kereiakes, DJ; Neutel, J; Shojaee, A; Stoakes, KA; Waverczak, WF; Xu, J, 2009)	0.69
" In each subgroup, > or =1 dosage combination of amlodipine + OM significantly reduced SeDBP and SeSBP compared with constituent monotherapies."	( Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. Karki, S; Lee, J; Melino, M; Oparil, S, 2009)	0.57
"Two simple, economical, rapid, precise, and accurate methods for simultaneous determination of olmesartan medoxomil and hydrochlorothiazide in combined tablet dosage form have been developed."	( Ratio spectra derivative and zero-crossing difference spectrophotometric determination of olmesartan medoxomil and hydrochlorothiazide in combined pharmaceutical dosage form. Bari, PD; Rote, AR, 2009)	0.79
" The method was applied successfully for the assay of olmesartan medoxomil in the tablet dosage form."	( RP-HPLC-DAD method for determination of olmesartan medoxomil in bulk and tablets exposed to forced conditions. Pancholi, SS; Sharma, RN, 2010)	0.88
" Since there is no monograph for this drug in tablets, the dissolution method presented here can be used as a quality control test for OLM in this dosage form, especially in a batch to batch evaluation."	( Development and validation of a discriminating in vitro dissolution method for a poorly soluble drug, olmesartan medoxomil: comparison between commercial tablets. Bajerski, L; Bergold, AM; Dias, CL; Fröehlich, PE; Rossi, RC, 2010)	0.58
" The larger blood pressure reduction obtained with O was particularly evident in the last 6 h from the dosing interval; a better homogeneity of the 24-h BP control with O was confirmed by higher smoothness indices."	( Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study. Auteri, A; Malacco, E; Omboni, S; Volpe, M; Zanchetti, A, 2010)	0.63
" The superiority of O was particularly evident in the last 4 h from the dosing interval."	( Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension. Barton, J; Mallion, JM; Narkiewicz, K; Omboni, S; Panzer, PK; Puig, JG; Stefanadis, C; Van Mieghem, W; Zweiker, R, 2011)	0.37
" In conclusion, adding HCTZ to OM 40 mg significantly improves BP reductions and target BP rates in harder-to-treat patients and a clear dose-response was observed for efficacy."	( Effects of high dose olmesartan medoxomil plus hydrochlorothiazide on blood pressure control in patients with grade 2 and grade 3 hypertension. Girerd, X; Rump, LC; Sellin, L; Stegbauer, J, 2011)	0.69
" In children and adolescents with hypertension (n = 302), oral olmesartan medoxomil significantly and dose-dependently reduced seated systolic blood pressure (BP) and seated dystolic BP from baseline (the primary endpoint) in a 3-week, dose-response period in a well designed phase II/III clinical trial."	( Olmesartan medoxomil: in children and adolescents with hypertension. Keating, GM; Muir, VJ, 2010)	2.04
" In conclusion, this amlodipine/OM-based titration regimen was well tolerated and effectively lowered BP throughout the 24-hour dosing interval in patients with hypertension and type 2 diabetes."	( Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimen. Littlejohn, T; Neutel, JM; Qian, C; Ram, CV; Sachson, R; Shojaee, A; Stoakes, KA, 2011)	0.6
" Secondary efficacy endpoints included the change from baseline in mean 24-hour ambulatory SBP; change from baseline in ambulatory BP during the daytime (8:00 am-4:00 pm), nighttime (10:00 pm-6:00 am) and the last 6, 4 and 2 hours of the dosing interval; change from baseline in SeBP at each titration step and at study end; and the proportion of patients achieving mean 24-hour ambulatory BP targets and SeBP goals at week 12."	( Blood pressure-lowering efficacy of an olmesartan medoxomil/hydrochlorothiazide-based treatment algorithm in elderly patients (age ≥65 years) stratified by age, sex and race: subgroup analysis of a 12-week, open-label, single-arm, dose-titration study. Kereiakes, DJ; Maa, JF; Neutel, J; Shojaee, A; Stoakes, KA; Waverczak, WF, 2011)	0.64
" Clinically significant ambulatory BP reductions were observed during the daytime, nighttime and the last 6, 4 and 2 hours of the dosing interval in all subgroups."	( Blood pressure-lowering efficacy of an olmesartan medoxomil/hydrochlorothiazide-based treatment algorithm in elderly patients (age ≥65 years) stratified by age, sex and race: subgroup analysis of a 12-week, open-label, single-arm, dose-titration study. Kereiakes, DJ; Maa, JF; Neutel, J; Shojaee, A; Stoakes, KA; Waverczak, WF, 2011)	0.64
" Simulations based on models developed in adult patients indicated that two dose groups were sufficient to estimate a dose-response relationship, thereby reducing by one-third the number of subjects required for the phase III pediatric study."	( The use of modeling and simulation to guide clinical development of olmesartan medoxomil in pediatric subjects. Carrothers, TJ; Heyrman, R; Rohatagi, S; Salazar, DE; Shi, J; Song, SH; Wada, DR, 2012)	0.61
"A simple, specific, accurate and precise stability-indicating reversed-phase high-performance liquid chromatographic method was developed for simultaneous estimation of olmesartan medoxomile (OLME), amlodipine besylate (AMLO) and hydrochlorothiazide (HCTZ) in tablet dosage form."	( Stability-indicating method for simultaneous estimation of olmesartan medoxomile, amlodipine besylate and hydrochlorothiazide by RP-HPLC in tablet dosage form. Chaudhari, AJ; Gorle, AP; Jain, PS; Patel, MK; Surana, SJ, 2012)	0.82
"An OM/HCTZ-based titration regimen enabled elderly patients with hypertension to safely reduce BP throughout the 24-hour dosing interval and allowed the majority of these patients to achieve a BP target of <140/90 mmHg or <140 mmHg."	( Efficacy of olmesartan medoxomil and hydrochlorothiazide fixed-dose combination therapy in patients aged 65 years and older with stage 1 and 2 hypertension or isolated systolic hypertension. Chavanu, KJ; Dubiel, R; Germino, FW; Maa, JF; Neutel, JM, 2012)	0.76
"The present study aimed at development of capsular dosage form of surface-adsorbed nanoemulsion (NE) of olmesartan medoxomil (OLM) so as to overcome the limitations associated with handling of liquid NEs without affecting their pharmaceutical efficacy."	( Product development studies on surface-adsorbed nanoemulsion of olmesartan medoxomil as a capsular dosage form. Bali, V; Pathak, K; Singh, S, 2012)	0.83
" Although the BP goals recommended in current consensus guidelines for the management of patients with hypertension are based on cuff BP measurements, ambulatory BP monitoring (ABPM) provides a valuable diagnostic tool and allows a more accurate assessment of BP levels throughout the 24-hour dosing period."	( Olmesartan medoxomil-based antihypertensive therapy evaluated by ambulatory blood pressure monitoring: efficacy in high-risk patient subgroups. Chrysant, SG; Germino, FW; Neutel, JM, 2012)	1.82
" Steady states of both compounds were attained after once-daily dosing for 8 days."	( Pharmacokinetic and pharmacodynamic profiles of a fixed-dose combination of olmesartan medoxomil and amlodipine in healthy Chinese males and females. Chen, X; Hu, P; Jiang, J; Liu, H; Liu, T; Zhao, Q; Zhong, W, 2012)	0.61
" Antihypertensive efficacy was maintained throughout the 24-hour dosing interval."	( Efficacy/safety of a fixed-dose amlodipine/olmesartan medoxomil-based treatment regimen in hypertensive blacks and non-blacks with uncontrolled BP on prior antihypertensive monotherapy. Maa, JF; Nesbitt, S; Shojaee, A, 2013)	0.65
" For the colesevelam coadministration periods, 3,750 mg once daily was dosed throughout the pharmacokinetic sampling period."	( The effects of colesevelam HCl on the single-dose pharmacokinetics of glimepiride, extended-release glipizide, and olmesartan medoxomil. He, L; Lee, J; Mendell-Harary, J; Tao, B; Walker, J; Wickremasingha, P; Wight, D, 2014)	0.61
" In stage 2, half of 28 subjects were daily dosed with regimen C for 7 days."	( Pharmacokinetics and tolerability of olmesartan medoxomil plus hydrochlorothiazide combination in healthy Chinese subjects: drug-drug interaction, bioequivalence, and accumulation. Hu, P; Jiang, J; Liu, DY; Wang, CG; Zhang, JY, 2014)	0.68
" The specificity of the developed methods is investigated by analyzing laboratory prepared mixtures containing different ratios of the three drugs and their combined dosage form."	( Spectrophotometric methods for simultaneous determination of ternary mixture of amlodipine besylate, olmesartan medoxomil and hydrochlorothiazide. Diab, SS; Merey, HA; Moustafa, AA; Ramadan, NK, 2014)	0.62
" The ANCOVA showed that changes in patients' HRQoL was likely to have been influenced by patients' achievement of blood pressure control, the amount of concomitant medication and patients' last used dosage strength of antihypertensive."	( Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension. Brazier, JE; Guest, JF; Haag, U; Marques da Silva, P; Soro, M, 2015)	0.65
" Achieving blood pressure control, amount of concomitant medication and dosage strength of antihypertensive impacted on patients' HRQoL."	( Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension. Brazier, JE; Guest, JF; Haag, U; Marques da Silva, P; Soro, M, 2015)	0.65
" Two different three-way analysis methods, PARAFAC and 3W-PLS1, were successfully applied to the quantitative estimation of the solid dosage form containing HCT and OLM."	( Three-way analysis of the UPLC-PDA dataset for the multicomponent quantitation of hydrochlorothiazide and olmesartan medoxomil in tablets by parallel factor analysis and three-way partial least squares. Dinç, E; Ertekin, ZC, 2016)	0.65
" AZL-M/CLD showed greater systolic BP reductions after initial dosing (P = ."	( Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease. Bakris, GL; Hisada, M; Juhasz, A; Kupfer, S; Lloyd, E; Oparil, S; Zhao, L, 2018)	0.71
" After all patients received any of OLM 10, 20, and 40 mg/day as an initial dose, the dosage of OLM was titrated up to 40 mg as needed during follow-up period."	( [Effects of Olmesartan Medoxomil on Patients with Thoracic and Thoracoabdominal Aortic Aneurysm;Evaluation of Anti-hypertensive Effect and Possible Suppression of Aneurysmal Dilation( OLM 40 Study)]. Adachi, O; Akiyama, M; Kumagai, K; Motoyoshi, N; Saiki, Y; Sasaki, K; Sato, M; Sugawara, Y, 2020)	0.94
"5 hours before dosing to 168 hours after dosing."	( Pharmacokinetics and Bioequivalence Evaluation of 2 Olmesartan Medoxomil and Amlodipine Besylate Fixed-Dose Combination Tablets in Healthy Chinese Volunteers Under Fasting and Fed Conditions. Chen, L; Li, X; Mo, E, 2022)	0.97
" The developed methods are accurate, precise, eco-friendly and could be applied successfully to estimate OLM and MET in their combined dosage form."	( Area under the curve and ratio difference spectrophotometric methods with evaluation of the greenness for simultaneous determination of olmesartan medoxomil and metoprolol succinate. Hammad, SF; Kamal, AH; Kamel, DN, 2023)	1.11

Class	Description
biphenyls	Benzenoid aromatic compounds containing two phenyl or substituted-phenyl groups which are joined together by a single bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathway	Proteins	Compounds
Metabolism	1496	1108
Biological oxidations	150	276
Phase I - Functionalization of compounds	69	175

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASE	Homo sapiens (human)	Potency	0.0224	0.0040	23.8416	100.0000	AID485290
Chain A, Cruzipain	Trypanosoma cruzi	Potency	7.9433	0.0020	14.6779	39.8107	AID1476
TDP1 protein	Homo sapiens (human)	Potency	33.4983	0.0008	11.3822	44.6684	AID686978
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	25.1189	0.0316	10.2792	39.8107	AID884; AID885
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Cellular tumor antigen p53	Homo sapiens (human)	Potency	33.4915	0.0023	19.5956	74.0614	AID651631
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	25.1189	1.0000	12.2248	31.6228	AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	2.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	28.5000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	4.7300	0.1100	7.1903	10.0000	AID1473738
Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)	IC50 (µMol)	0.9772	0.1047	2.7195	7.0795	AID977603
Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)	Ki	0.7500	0.0800	2.4688	9.8000	AID977604
Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)	IC50 (µMol)	0.9772	0.0500	2.3797	9.7000	AID977600
Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)	Ki	0.5400	0.0440	1.3630	5.0000	AID977601
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
cellular response to starvation	Albumin	Homo sapiens (human)
negative regulation of mitochondrial depolarization	Albumin	Homo sapiens (human)
cellular response to calcium ion starvation	Albumin	Homo sapiens (human)
cellular oxidant detoxification	Albumin	Homo sapiens (human)
transport	Albumin	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
lipid metabolic process	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
xenobiotic metabolic process	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
androgen metabolic process	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
estrogen metabolic process	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
cellular glucuronidation	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
monoatomic ion transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
organic anion transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
bile acid and bile salt transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
heme catabolic process	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
sodium-independent organic anion transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
transmembrane transport	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
xenobiotic metabolic process	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
monoatomic ion transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
organic anion transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
bile acid and bile salt transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
prostaglandin transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
heme catabolic process	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
sodium-independent organic anion transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
transmembrane transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
thyroid hormone transport	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
oxygen binding	Albumin	Homo sapiens (human)
DNA binding	Albumin	Homo sapiens (human)
fatty acid binding	Albumin	Homo sapiens (human)
copper ion binding	Albumin	Homo sapiens (human)
protein binding	Albumin	Homo sapiens (human)
toxic substance binding	Albumin	Homo sapiens (human)
antioxidant activity	Albumin	Homo sapiens (human)
pyridoxal phosphate binding	Albumin	Homo sapiens (human)
identical protein binding	Albumin	Homo sapiens (human)
protein-folding chaperone binding	Albumin	Homo sapiens (human)
exogenous protein binding	Albumin	Homo sapiens (human)
enterobactin binding	Albumin	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
retinoic acid binding	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
glucuronosyltransferase activity	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
serine-type endopeptidase inhibitor activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
bile acid transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
bile acid transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
sodium-independent organic anion transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
thyroid hormone transmembrane transporter activity	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
extracellular region	Albumin	Homo sapiens (human)
extracellular space	Albumin	Homo sapiens (human)
nucleus	Albumin	Homo sapiens (human)
endoplasmic reticulum	Albumin	Homo sapiens (human)
endoplasmic reticulum lumen	Albumin	Homo sapiens (human)
Golgi apparatus	Albumin	Homo sapiens (human)
platelet alpha granule lumen	Albumin	Homo sapiens (human)
extracellular exosome	Albumin	Homo sapiens (human)
blood microparticle	Albumin	Homo sapiens (human)
protein-containing complex	Albumin	Homo sapiens (human)
cytoplasm	Albumin	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum membrane	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
membrane	UDP-glucuronosyltransferase 2B7	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
basal plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
basolateral plasma membrane	Solute carrier organic anion transporter family member 1B3	Homo sapiens (human)
plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
basal plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
basolateral plasma membrane	Solute carrier organic anion transporter family member 1B1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Assay ID	Title	Year	Journal	Article
AID540299	A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis	2010	Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21	Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519	A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities	2011	Antiviral research, Sep, Volume: 91, Issue:3	High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID731531	Half life in simulated gastric juice at 1 uM	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Discovery of olmesartan hexetil: a new potential prodrug of olmesartan.
AID625288	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1223385	Prodrug conversion in human plasma assessed as hydrolysis measured per mg of protein at 10 uM in presence of Ca2+	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID731530	Half life in rat plasma at 1 uM	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Discovery of olmesartan hexetil: a new potential prodrug of olmesartan.
AID1223389	Prodrug conversion in recombinant human PON1 192QQ mutant expressed in FreeStyle 293-F cells assessed as hydrolysis measured per mg of protein at 10 uM in presence of Mg2+	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID516519	Tmax in Sprague-Dawley rat at 20 mg/kg, po	2010	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19	Novel amides and esters prodrugs of olmesartan: Synthesis, bioconversion, and pharmacokinetic evaluation.
AID1223396	Prodrug conversion in human serum albumin assessed as hydrolysis measured per mg of protein at 10 uM in presence of Zn2+	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID1223416	Prodrug conversion in human serum LPDS assessed as conversion velocity per mg of protein at 10 uM in presence of KPB	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID731529	Half life in rat liver microsomes at 1 uM	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Discovery of olmesartan hexetil: a new potential prodrug of olmesartan.
AID977604	Ki values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1223403	Prodrug conversion in recombinant human PON1 192RR mutant expressed in FreeStyle 293-F cells assessed as hydrolysis by single-enzyme Michaelis-Menten model	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID1223398	Prodrug conversion in human plasma assessed as hydrolysis measured per mg of protein by single-enzyme Michaelis-Menten model	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID754087	Oral bioavailability in human	2013	European journal of medicinal chemistry, Jun, Volume: 64	Synthesis and pharmacological properties of a new hydrophilic and orally bioavailable 5-HT4 antagonist.
AID625290	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID699539	Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID613235	Cmax in Sprague-Dawley rat plasma at 20 mg/kg, po after 10 hrs by LC-MS/MS analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design, synthesis, bioconversion, and pharmacokinetics evaluation of new ester prodrugs of olmesartan.
AID1223392	Prodrug conversion in recombinant human PON1 192RR mutant expressed in FreeStyle 293-F cells assessed as hydrolysis measured per mg of protein at 10 uM in presence of Mg2+	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID977600	pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID625282	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1737435	Agonist activity at human PPARgammaDEF receptor expressed in african green monkey COS7 cells transfected with pGal5-TK-pGL3/pRenilla-CMV assessed as intrinsic activity measured after 39 hrs by dual luciferase reporter assay	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID1223415	Prodrug conversion in human serum LPDS assessed as conversion velocity per mg of protein at 10 uM in presence of Tris-HCl/Ca2+	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID1223418	Prodrug conversion in human serum LDL assessed as distribution of hydrolyzing activity measured per ml of serum at 10 uM in presence of Tris-HCl/Ca2+	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1223406	Prodrug conversion in human serum albumin assessed as hydrolysis by single-enzyme Michaelis-Menten model	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID977599	Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1223391	Prodrug conversion in recombinant human PON1 192RR mutant expressed in FreeStyle 293-F cells assessed as hydrolysis measured per mg of protein at 10 uM in presence of Ca2+	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID1223405	Ratio of Vmax to Km in recombinant human PON1 192RR mutant expressed in FreeStyle 293-F cells assessed as hydrolysis measured per mg of protein by single-enzyme Michaelis-Menten model	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID1474009	Ratio of drug concentration at steady state in human at 20 to 40 mg, po QD after 24 hrs to IC50 for human MRP3 overexpressed in Sf9 insect cells	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1223407	Prodrug conversion in human serum albumin assessed as hydrolysis measured per mg of protein by single-enzyme Michaelis-Menten model	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID1737437	Cytotoxicity against African green monkey COS7 cells assessed as effect on metabolic activity at 20 uM measured after 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID1223397	Prodrug conversion in human plasma assessed as hydrolysis by single-enzyme Michaelis-Menten model	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID1473835	Stimulation of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1223411	Prodrug conversion in purified albumin (unknown origin) assessed as hydrolysis in presence of 4 fold anti-PON1 IgG/plasma ratio	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID588212	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625292	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1737443	Cytotoxicity against human HS5 cells assessed as cell death at 10 uM measured after 72 hrs by Propidium iodide stain based FACS analysis	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID588211	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1223421	Prodrug conversion in human serum LPDS assessed as distribution of hydrolyzing activity measured per ml of serum at 10 uM in presence of KPB	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID625280	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1808091	Drug metabolism in mini gut model assessed as metabolite formation by LC-MS/MS analysis	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach.
AID1223413	Prodrug conversion in human serum LDL assessed as conversion velocity at 10 uM measured per mg of protein in presence of Tris-HCl/Ca2+	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID1223400	Prodrug conversion in recombinant human PON1 192QQ mutant expressed in FreeStyle 293-F cells assessed as hydrolysis by single-enzyme Michaelis-Menten model	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID1223417	Prodrug conversion in human serum VLDL and chylomicron assessed as distribution of hydrolyzing activity measured per ml of serum at 10 uM in presence of Tris-HCl/Ca2+	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID625287	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474007	Drug concentration at steady state in human at 20 to 40 mg, po QD after 24 hrs	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1808092	Drug metabolism in human gut microbes assessed as metabolite formation by LC-MS/MS analysis	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach.
AID1223412	Prodrug conversion in human serum VLDL and chylomicron assessed as conversion velocity at 10 uM measured per mg of protein in presence of Tris-HCl/Ca2+	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID613236	Stability of the compound in rat liver microsomes assessed as half life at 1 uM by LC/MS/MS analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design, synthesis, bioconversion, and pharmacokinetics evaluation of new ester prodrugs of olmesartan.
AID1223387	Prodrug conversion in human plasma assessed as hydrolysis measured per mg of protein at 10 uM in presence of Zn2+	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID613234	AUC (0 to last) in Sprague-Dawley rat plasma at 20 mg/kg, po after 10 hrs by LC-MS/MS analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design, synthesis, bioconversion, and pharmacokinetics evaluation of new ester prodrugs of olmesartan.
AID699541	Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1223388	Prodrug conversion in recombinant human PON1 192QQ mutant expressed in FreeStyle 293-F cells assessed as hydrolysis measured per mg of protein at 10 uM in presence of Ca2+	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID1808093	Stability of compound in mini gut model at 24 hrs by LC-MS analysis	2021	Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23	Searching for New Microbiome-Targeted Therapeutics through a Drug Repurposing Approach.
AID1737436	Cytotoxicity against African green monkey COS7 cells assessed as effect on metabolic activity at 10 uM measured after 72 hrs by MTT assay	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID977603	pIC50 values for sodium fluorescein (10 uM) uptake in OATP1B3-transfected CHO cells	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID731527	Tmax in Sprague-Dawley rat assessed as olmesartan at 20 mg/kg, po	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Discovery of olmesartan hexetil: a new potential prodrug of olmesartan.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID516517	Cmax in Sprague-Dawley rat at 20 mg/kg, po	2010	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19	Novel amides and esters prodrugs of olmesartan: Synthesis, bioconversion, and pharmacokinetic evaluation.
AID1474008	Ratio of drug concentration at steady state in human at 20 to 40 mg, po QD after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1223404	Prodrug conversion in recombinant human PON1 192RR mutant expressed in FreeStyle 293-F cells measured per mg of protein by single-enzyme Michaelis-Menten model	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID1223414	Prodrug conversion in human serum HDL assessed as conversion velocity per mg of protein at 10 uM in presence of Tris-HCl/Ca2+	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID625285	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1223410	Prodrug conversion in human serum albumin assessed as hydrolysis in presence of 4 fold anti-PON1 IgG/plasma ratio	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID1223419	Prodrug conversion in human serum HDL assessed as distribution of hydrolyzing activity measured per ml of serum at 10 uM in presence of Tris-HCl/Ca2+	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID613239	Tmax in Sprague-Dawley rat plasma at 20 mg/kg, po after 10 hrs by LC-MS/MS analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design, synthesis, bioconversion, and pharmacokinetics evaluation of new ester prodrugs of olmesartan.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1223393	Prodrug conversion in recombinant human PON1 192RR mutant expressed in FreeStyle 293-F cells assessed as hydrolysis measured per mg of protein at 10 uM in presence of Zn2+	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID625286	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1223386	Prodrug conversion in human plasma assessed as hydrolysis measured per mg of protein at 10 uM in presence of Mg2+	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID1223402	Ratio of Vmax to Km in recombinant human PON1 192QQ mutant expressed in FreeStyle 293-F cells assessed as hydrolysis measured per mg of protein by single-enzyme Michaelis-Menten model	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID1737434	Agonist activity at human PPARgammaDEF receptor expressed in african green monkey COS7 cells transfected with pGal5-TK-pGL3/pRenilla-CMV assessed as maximal activation at 10 uM measured after 39 hrs by dual luciferase reporter assay relative to pioglitazo	2020	European journal of medicinal chemistry, Jun-01, Volume: 195	Identification and development of non-cytotoxic cell death modulators: Impact of sartans and derivatives on PPARγ activation and on growth of imatinib-resistant chronic myelogenous leukemia cells.
AID699540	Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting	2012	Journal of medicinal chemistry, May-24, Volume: 55, Issue:10	Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1223399	Ratio of Vmax to Km in human plasma assessed as hydrolysis measured per mg of protein by single-enzyme Michaelis-Menten model	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID731065	AUClast in Sprague-Dawley rat assessed as olmesartan at 20 mg/kg, po	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Discovery of olmesartan hexetil: a new potential prodrug of olmesartan.
AID625291	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1223401	Prodrug conversion in recombinant human PON1 192QQ mutant expressed in FreeStyle 293-F cells measured per mg of protein by single-enzyme Michaelis-Menten model	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID625281	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID613240	Stability of the compound in simulated gastric juice assessed as half life at 1 uM by LC/MS/MS analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design, synthesis, bioconversion, and pharmacokinetics evaluation of new ester prodrugs of olmesartan.
AID1474006	AUC in human at 20 to 40 mg, po QD after 24 hrs	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1223390	Prodrug conversion in recombinant human PON1 192QQ mutant expressed in FreeStyle 293-F cells assessed as hydrolysis measured per mg of protein at 10 uM in presence of Zn2+	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID1474010	Ratio of drug concentration at steady state in human at 20 to 40 mg, po QD after 24 hrs to IC50 for human MRP4 overexpressed in Sf9 insect cells	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1223394	Prodrug conversion in human serum albumin assessed as hydrolysis measured per mg of protein at 10 uM in presence of Ca2+	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID1223408	Ratio of Vmax to Km in human serum albumin assessed as hydrolysis measured per mg of protein by single-enzyme Michaelis-Menten model	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID516520	AUC (0 to last) in Sprague-Dawley rat at 20 mg/kg, po	2010	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 20, Issue:19	Novel amides and esters prodrugs of olmesartan: Synthesis, bioconversion, and pharmacokinetic evaluation.
AID613237	Stability of the compound in rat plasma assessed as half life at 1 uM by LC/MS/MS analysis	2011	European journal of medicinal chemistry, Sep, Volume: 46, Issue:9	Design, synthesis, bioconversion, and pharmacokinetics evaluation of new ester prodrugs of olmesartan.
AID977602	Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID588213	Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents	2010	Chemical research in toxicology, Jan, Volume: 23, Issue:1	Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625289	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID731528	Cmax in Sprague-Dawley rat assessed as olmesartan at 20 mg/kg, po	2013	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 23, Issue:5	Discovery of olmesartan hexetil: a new potential prodrug of olmesartan.
AID977601	Ki values for sodium fluorescein (10 uM) uptake in OATP1B1-transfected CHO cells	2013	Molecular pharmacology, Jun, Volume: 83, Issue:6	Structure-based identification of OATP1B1/3 inhibitors.
AID1223420	Prodrug conversion in human serum LPDS assessed as distribution of hydrolyzing activity measured per ml of serum at 10 uM in presence of Tris-HCl/Ca2+	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID1223395	Prodrug conversion in human serum albumin assessed as hydrolysis measured per mg of protein at 10 uM in presence of Mg2+	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID625279	Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia	2011	PLoS computational biology, Dec, Volume: 7, Issue:12	Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1223409	Prodrug conversion in human plasma assessed as hydrolysis in presence of 4 fold anti-PON1 IgG/plasma ratio	2012	Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 40, Issue:2	Paraoxonase 1 as a major bioactivating hydrolase for olmesartan medoxomil in human blood circulation: molecular identification and contribution to plasma metabolism.
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1159550	Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening	2015	Nature cell biology, Nov, Volume: 17, Issue:11	6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1346995	Human AT1 receptor (Angiotensin receptors)	2001	Journal of hypertension. Supplement : official journal of the International Society of Hypertension, Jun, Volume: 19, Issue:1	In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	5 (1.11)	18.2507
2000's	218 (48.44)	29.6817
2010's	195 (43.33)	24.3611
2020's	32 (7.11)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	119 (25.93%)	5.53%
Reviews	70 (15.25%)	6.00%
Case Studies	11 (2.40%)	4.05%
Observational	7 (1.53%)	0.25%
Other	252 (54.90%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (102)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
Phase IV Study for Effect of Intensive Blood-Pressure Control Using Anti-hypertensive Agents in Essential Hypertension With History of Stroke [NCT01198496]	Phase 4	5,000 participants (Anticipated)	Interventional	2010-10-31	Recruiting
Single Dose Crossover Comparative Bioavailability Study of Olmesartan Medoxomil 40 mg Film-coated Tablets in Healthy Adult Subjects Under Fasting Conditions. [NCT03951051]	Phase 1	32 participants (Actual)	Interventional	2019-05-06	Completed
A Phase 3, Double-Blind, Randomized, Parallel-Group Study to Evaluate the Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension [NCT02407210]	Phase 3	304 participants (Anticipated)	Interventional	2015-01-31	Recruiting
Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis Progression and Epicardial Adipose Tissue(EAT) Volume Reduction in Patients With Coronary Atherosclerosis Detected by Coronary CT Angiography(CCTA) [NCT02360956]	Phase 4	100 participants (Anticipated)	Interventional	2014-12-31	Recruiting
An Open-label, Randomized, 2X2 Crossover Study to Compare the Pharmacokinetics and Safety Between DWJ1351 and Co-administration of Amlodipine/Olmesartan and Rosuvastatin in Healthy Male Subjects [NCT03753477]	Phase 1	64 participants (Actual)	Interventional	2017-12-22	Completed
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of Olmesartan/Amlodipine/Rosuvastatin Combination Treatment in Patients With Concomitant Hypertension and Hyperlipidemia [NCT03009487]	Phase 3	265 participants (Actual)	Interventional	2017-01-31	Completed
A Multi-center, Prospective, Observational Study to Evaluate the Therapeutic Effectiveness and Safety of Olomax Tab. for Patients With Hypertension and Dyslipidemia [NCT05184179]		7,000 participants (Anticipated)	Observational	2019-12-01	Enrolling by invitation
A Prospective, Open Label, Single Arm Study to Evaluate the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen in Type II Diabetic Patients With Hypertension [NCT00403481]	Phase 4	192 participants (Actual)	Interventional	2006-11-30	Completed
A Randomized, Double-blind, Active Control, 3-parallel Group, Forced Titration, Multicenter, Phase IV Study to Evaluate the Efficacy and Safety of Fimasartan Versus Valsartan Monotherapy in Patients With Mild to Moderate Essential Hypertension [NCT02495324]	Phase 4	369 participants (Actual)	Interventional	2015-06-30	Completed
An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of Olmesartan Medoxomil Tablets 40 mg [Torrent,India] Versus Benicar 40 mg Tablets [Daiichi Sankyo Inc., USA] in Healthy Subjects-Fed Condition. [NCT03319706]	Phase 1	34 participants (Actual)	Interventional	2010-08-31	Completed
Efficacy and Safety of Hydrochlorothiazide (HCTZ) Used as Add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil (OM) 40 mg Monotherapy [NCT00430508]	Phase 3	972 participants (Actual)	Interventional	2007-02-28	Completed
Comparison of the Efficacy of Olmesartan Medoxomil Versus Nitrendipine on Systolic Blood Pressure in Elderly and Very Elderly Patients With Isolated Systolic Hypertension [NCT00751829]	Phase 3	417 participants (Actual)	Interventional	2003-07-31	Completed
A Randomized, Double Blind Study To Compare The Effects Of Olmesartan Medoxomil Versus Placebo In Patients With Established Atherosclerosis [NCT00382213]	Phase 3	210 participants	Interventional	2000-06-30	Completed
Add-on Study of CCBs or Diuretics in Essential Hypertension Not Achieving Target Blood Pressure on Olmesartan Medoxomil Alone [NCT00858702]	Phase 4	105 participants (Actual)	Interventional	2005-02-28	Completed
Efficacy and Safety of Olmesartan Medoxomil/Hydrochlorothiazide Combination 20/25 mg Versus 40/25 mg in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 40 mg Monotherapy [NCT00430950]	Phase 3	1,011 participants (Actual)	Interventional	2007-02-28	Completed
A Prospective, Open Label, Single Arm Study to Evaluation the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen in Elderly Patients With Hypertension [NCT00412932]	Phase 4	178 participants (Actual)	Interventional	2006-12-31	Completed
Effects of Angiotensin-Receptor Blockade With Olmesartan on Carotid Atherosclerosis in Patients With Hypertension: The Confirmatory Olmesartan Plaque Regression Study [NCT01132768]	Phase 4	114 participants (Actual)	Interventional	2010-05-31	Terminated(stopped due to Low recruitment)
A TElmisartan and AMlodipine STudy to Assess the Cardiovascular PROTECTive Effects as Measured by Endothelial Dysfunction in Hypertensive at Risk Patients Beyond Blood Pressure [NCT01180205]	Phase 4	576 participants (Anticipated)	Interventional	2010-08-31	Active, not recruiting
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Subjects With Essential Hypertension [NCT00696241]	Phase 3	1,275 participants (Actual)	Interventional	2007-06-30	Completed
A Phase 3, Open-Label, Randomized, Long-Term Comparison of the Safety and Tolerability of the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs. Olmesartan Medoxomil-Hydrochlorothiazide Fixed-Dose Combination in Subjects With Essential Hypertension [NCT00996281]	Phase 3	837 participants (Actual)	Interventional	2009-10-31	Completed
Effect of Olmesartan Medoxomil on Arterial Stiffness and Thickness in Subjects With Metabolic Syndrome [NCT00676845]	Phase 3	133 participants (Actual)	Interventional	2008-08-31	Completed
A Post Marketing Surveillance, Multicenter, Open-Label, Dose-Titrating, 4-Week Study Evaluating The Efficacy, Tolerability And Safety Of Olmesartan Medoxomil 20mg In Combination With 12.5mg Hydrochlorothiazide In Subjects With Stage 1 To Stage 2 Hypertens [NCT00796159]		1,723 participants (Actual)	Observational	2007-07-31	Completed
A Prospective, Open-label, Ambulatory Blood Pressure Monitoring (ABPM) Dose Titration Study to Evaluate the Safety and Efficacy of an Olmesartan Medoxomil and Amlodipine Based Treatment Regimen in Hypertensive, Type 2 Diabetic Subjects [NCT00654745]	Phase 4	207 participants (Actual)	Interventional	2008-05-31	Completed
Reduction Efficacy of OLOMAX for Blood Pressure and Low-density Lipoprotein Cholesterol in Hypertensive Patients With Dyslipidemia: a Multi-center-database Real-world Study [NCT05660135]		4,000 participants (Anticipated)	Observational	2022-06-20	Recruiting
A Non-interventional, Multi Center, Prospective Observational Study to Evaluate the Effect of Improving Systolic Blood Pressure and Low-density Lipoprotein Cholesterol Compared to Conventional Treatments and the Convenience of Taking Medication of Olostar [NCT05411887]		3,000 participants (Anticipated)	Observational	2022-06-20	Recruiting
Comparison of the Efficacy of Olmesartan Medoxomil Versus Losartan on Diastolic Blood Pressure in Elderly and Very Elderly Patients With Essential Hypertension. [NCT00751751]	Phase 3	441 participants (Actual)	Interventional	2003-06-30	Completed
Vascular Improvement With Olmesartan Medoxomil Study [NCT00772499]	Phase 4	100 participants (Actual)	Interventional	2002-11-30	Completed
CS-866DM Phase 3 Clinical Study: A Double-Blind Controlled Trial in Patients With Diabetic Nephropathy and Overt Proteinuria Secondary to Type 2 Diabetes Mellitus [NCT00141453]	Phase 3	577 participants (Actual)	Interventional	2003-04-30	Completed
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]		22,213 participants (Actual)	Observational	2020-01-19	Completed
Single-Dose Fed In Vivo Bioequivalence Study of Olmesartan Medoxomil Tablets (40 mg; Mylan) to Benicar® Tablets (40 mg; Sankyo) in Healthy Volunteers [NCT00648219]	Phase 1	36 participants (Actual)	Interventional	2005-12-31	Completed
Single-Dose Fasting In Vivo Bioequivalence Study of Olmesartan Medoxomil Tablets (40 mg; Mylan) to Benicar® Tablets (40 mg; Sankyo) in Healthy Volunteers [NCT00649623]	Phase 1	36 participants (Actual)	Interventional	2005-12-31	Completed
A Randomized, Double-blind, Double-dummy, Multi-center Study to Investigate the Safety and Efficacy of Olmesartan Medoxomil Compared With Losartan Potassium in Patients With Mild to Moderate Essential Hypertension [NCT00856271]	Phase 3	287 participants (Actual)	Interventional	2004-08-31	Completed
A Prospective, Open-label Study to Assess the Efficacy and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Subjects With Stage 1 and Stage 2 Hypertension [NCT00527514]	Phase 3	185 participants (Actual)	Interventional	2007-09-30	Completed
A 24-Week Multicentre, Randomized, Double-Blind, Controlled, Parallel Group Non-Inferiority Study to Assess the Efficacy and Safety of Olmesartan Medoxomil Versus Candesartan Cilexetil in Patients With Symptomatic Heart Failure (NYHA II-IV) [NCT00679484]	Phase 3	400 participants (Anticipated)	Interventional	2008-06-30	Terminated(stopped due to Lack of subject recruitment)
A Phase 3, Double-Blind, Randomized, Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Benicar HCT® (Olmesartan Medoxomil-Hydrochlorothiazide) in Subjects With Moderate to Severe Essential Hypertension [NCT00846365]	Phase 3	1,085 participants (Actual)	Interventional	2009-03-31	Completed
[NCT02561884]	Phase 1	58 participants (Actual)	Interventional	2015-10-31	Enrolling by invitation
A Prospective, Open-Label, Titration Study to Evaluate the Efficacy and Safety Safety of AZOR in Multiple Subgroups of Hypertensive Subjects Who Are Non-Responders to Anti-Hypertensive Monotherapy [NCT00791258]	Phase 4	999 participants (Actual)	Interventional	2008-11-30	Completed
A Multi-center, Randomized, Double-blind, Double-dummy, With Olmesartan Medoxomil as Positive Control Parallel Clinical Study to Evaluate the the Safety and Efficacy of Azilsartan in Chinese Patients With Primary Mild and Moderate Hypertension [NCT02609490]	Phase 3	304 participants (Actual)	Interventional	2015-09-30	Completed
Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk Assessment [NCT00741585]	Phase 4	21,983 participants (Actual)	Interventional	2008-09-01	Completed
A Phase 3b, Double-Blind, Randomized, 12-Week Efficacy and Safety Study Comparing the TAK-491 Plus Chlorthalidone Fixed-Dose Combination vs Olmesartan Medoxomil-Hydrochlorothiazide in Subjects With Moderate to Severe Hypertension [NCT01033071]	Phase 3	1,071 participants (Actual)	Interventional	2010-01-31	Completed
AN OPEN LABEL, NON-INTERVENTIONAL STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF AMLODIPINE AND OLMESARTAN MEDOXOMIL (NORMETECTM) IN FILIPINO PATIENTS WITH HYPERTENSION: A POST MARKETING SURVEILLANCE STUDY [NCT01200407]		615 participants (Actual)	Observational	2010-06-09	Terminated(stopped due to The requirement for Post Marketing Surveillance was lifted by the Philippine FDA)
A Multi-center, Randomized, Double-Blind, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DWJ1451 in Patients With Hypertension and Dyslipidemia [NCT04161001]	Phase 3	237 participants (Anticipated)	Interventional	2019-11-20	Recruiting
A Randomized, Double-Blind, Parallel Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Subjects With Hypertension [NCT00649389]	Phase 3	2,500 participants (Actual)	Interventional	2008-05-31	Completed
Randomised, Double-Blind, Parallel-Group Study Evaluating Efficacy and Safety of Co-Administration of Triple Combinations of Olmesartan Medoxomil, Amlodipine Besylate, and Hydrochlorothiazide Compared With Corresponding Olmesartan - Amlodipine Combination [NCT00923091]	Phase 3	2,689 participants (Actual)	Interventional	2009-06-30	Completed
Effect of Olmesartan Medoxomil on Vascular Markers in Hypertensive Patients With Metabolic Syndrome [NCT00891267]	Phase 3	60 participants (Anticipated)	Interventional	2008-10-31	Completed
Single-Dose Fed Bioequivalence Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets (40 mg/25 mg; Mylan) to Benicar HCT® Tablets (40 mg/25 mg; Sankyo) in Healthy Volunteers [NCT01019590]	Phase 1	36 participants (Actual)	Interventional	2006-11-30	Completed
Single-Dose Fasting Bioequivalence Study of Olmesartan Medoxomil and Hydrochlorothiazide Tablets (40 mg/25 mg; Mylan) to Benicar HCT® Tablets (40 mg/25 mg; Sankyo) in Healthy Volunteers [NCT01020214]	Phase 1	36 participants (Actual)	Interventional	2006-11-30	Completed
A Randomized, Double-blind, Active-comparator, 8-week Forced-titration Study of the Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Hypertensive Subjects [NCT00949884]	Phase 4	941 participants (Actual)	Interventional	2009-08-31	Completed
Single Dose Crossover Comparative Bioavailability Study of Olmesartan Medoxomil/Hydrochlorothiazide 40 mg/25 mg Film-Coated Tablets in Healthy Adult Subjects / Fasting State [NCT04138888]	Phase 1	32 participants (Anticipated)	Interventional	2019-10-31	Recruiting
An Exploratory Study of CS-3150 to Evaluate the Relation Between Antihypertensive Effect and Baseline Factors Compared to Olmesartan Medoxomil in Patients With Essential Hypertension [NCT02848170]		40 participants (Actual)	Interventional	2016-08-31	Completed
Add-on Study of Hydrochlorothiazide in Patients With Moderate to Severe Hypertension Not Achieving Target Blood Pressure on Olmesartan/Amlodipine Alone [NCT00902538]	Phase 3	2,204 participants (Actual)	Interventional	2009-04-30	Completed
An Open-label Study of Olmesartan Medoxomil (CS-866) in Normotensive Patients With Chronic Glomerulonephritis or Diabetic Nephropathy [NCT00914524]	Phase 2	49 participants (Actual)	Interventional	2005-01-31	Completed
An Open-label, Multicenter Study to Evaluate the Efficacy and Tolerability of a 4 Week Therapy With the Fixed Dose Combination of Amlodipine 10 mg Plus Valsartan 160 mg in Hypertensive Patients Not Adequately Responding to a 4 Week Therapy With the Free C [NCT00523744]	Phase 3	257 participants (Actual)	Interventional	2007-07-31	Completed
Treat-to-Target Study of Olmesartan Medoxomil and an Add-on Treatment Algorithm Consisting of Hydrochlorothiazide and Amlodipine Besylate in Patients With Mild to Moderate Hypertension [NCT00311155]	Phase 4	694 participants (Actual)	Interventional	2006-03-31	Completed
A Clinical Trial of Renin Profiling in Selection of Initial Antihypertensive Drug [NCT00834600]		185 participants (Actual)	Interventional	2005-12-31	Completed
Efficacy and Safety of Olmesartan Medoxomil Compared With Losartan in Patients With Hypertension and Mild to Moderate Renal Impairment [NCT00151827]	Phase 3	393 participants (Actual)	Interventional	2003-08-31	Completed
A Randomized, Double-blind, Double-dummy, Multicenter Clinical Trial to Evaluate the Additional Efficacy and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension [NCT00872586]	Phase 3	304 participants (Actual)	Interventional	2006-08-31	Completed
Prospective, Multicentric, Open Clinic Essay to Evaluate the Use of OLMETEC® (Olmesartan Medoxomile) and OLMETEC PLUS® (Olmesartan Medoxomile Hydrochlorothiazide) in Stade I and II, According to JNC VII [NCT00811226]		450 participants (Anticipated)	Observational	2007-04-30	Completed
Comparison of the Effects of Different Antihypertensive Drugs in Patients With Hypertension and Obstructive Sleep Apnea [NCT01028534]		150 participants (Anticipated)	Interventional	2010-07-31	Completed
A Double-Blind, Randomized, Placebo Controlled, Parallel Group Study to Compare the Safety and Efficacy of an Olmesartan Medoxomil Based Treatment Regimen to Placebo in Patients With Stage I and Stage II Hypertension [NCT00430638]	Phase 4	278 participants (Actual)	Interventional	2006-12-31	Completed
Effect of Probenecid on Pharmacokinetics, and Tolerability of Olmesartan in Healthy Chinese Volunteers [NCT01907373]	Phase 4	12 participants (Actual)	Interventional	2009-08-31	Completed
The Japan-Combined Treatment With Olmesartan and a Calcium Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study (J-CORE) [NCT00607035]	Phase 4	220 participants (Actual)	Interventional	2006-05-31	Completed
A Randomized, Open Label, Multiple-Dose, Cross-over Clinical Study to Investigate Pharmacokinetics and Drug-Drug Interaction Between Rosuvastatin and CS-866 in Healthy Male Volunteers [NCT01415466]	Phase 1	36 participants (Actual)	Interventional	2011-08-31	Completed
The Relative Effects of Single Doses of Olmesartan Medoxomil, Irbesartan and Valsartan at High Dosage Levels on the Renin-Angiotensin-Aldosterone System in Healthy Normal Subjects [NCT00185055]	Phase 4	20 participants	Interventional	2004-11-30	Completed
The Effects of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on Insulin Sensitivity in Overweight and Obese Subjects With Hypertension [NCT00185094]	Phase 4	60 participants	Interventional	2004-02-29	Completed
A Randomized, Double-blind, Placebo-controlled Factorial Study Evaluating the Efficacy and Safety of Co-administration of Olmesartan Medoxomil Plus Amlodipine Compared to Monotherapy in Patients With Mild to Severe Hypertension [NCT00185133]	Phase 3	1,900 participants	Interventional	2005-05-31	Completed
A Study on the Efficacy and Safety of Olmesartan Medoxomil and Its Combination With Hydrochlorothiazide Compared With an ACE Inhibitor and Its Combination With a Calcium Channel Blocker in Patients With Stage 2 Hypertension [NCT00185120]	Phase 4	152 participants	Interventional	2005-09-30	Completed
Randomized Olmesartan and Diabetes Microalbuminuria Prevention Study (ROADMAP) [NCT00185159]	Phase 3	4,449 participants (Actual)	Interventional	2004-10-31	Completed
Add-on Study of Olmesartan Medoxomil in Patients With Moderate to Severe Hypertension Not Achieving Target Blood Pressure on Amlodipine 5 mg Alone [NCT00220233]	Phase 3	632 participants	Interventional	2005-04-30	Completed
A Randomized, Open Label, Single-Dose, 2-Way Cross-over Clinical Trial to Compare the Safety and Pharmacokinetic Characteristics of Combination of Rosuvastatin and CS-866 and DWJ1276 in Healthy Male Volunteers [NCT01493856]	Phase 1	58 participants (Actual)	Interventional	2012-01-31	Completed
Combination of OLMesartan and Calcium Channel Blocker or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study) [NCT00454662]	Phase 4	5,141 participants (Actual)	Interventional	2007-04-30	Completed
Multi-Omics to Predict the Blood Pressure Response to Antihypertensives [NCT05917275]	Phase 4	96 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
[NCT01831479]	Phase 1	36 participants (Actual)	Interventional	2011-08-31	Completed
An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of FDC of Olmesaartan Medoxomil, Amlopdipine and Hydrochlorothiazide (40+10+25) mg Tab [Torrent,India] Vs Tribenzor(40+10+25) mg Tab [ Daichi Sankyo, Inc USA] in Health [NCT02962336]	Phase 1	34 participants (Actual)	Interventional	2011-05-31	Completed
The Study Comparing the Incidence of Cardiovascular Events Between High-dose ARB Monotherapy and Combination Therapy With ARB and Calcium Channel Blocker in Japanese Elderly Hypertensive Patients at High Cardiovascular Risk [NCT00134160]	Phase 4	1,000 participants (Anticipated)	Interventional	2005-08-31	Completed
Efficacy and Safety of Olmesartan: Reduction of Blood Pressure in the Treatment of Patients Suffering From Mild to Moderate Essential Hypertension [NCT00185172]	Phase 3	2,333 participants (Actual)	Interventional	2002-01-31	Completed
Efficacy and Safety of Amlodipine Used as add-on Therapy in Moderately to Severely Hypertensive Patients Not Adequately Controlled by Olmesartan Medoxomil 20 mg Monotherapy [NCT00220220]	Phase 3	429 participants (Anticipated)	Interventional	2005-04-30	Completed
A Randomized, Open-Label, Phase 3 Study to Compare Long-Term Safety and Tolerability of the TAK-491 and Chlorthalidone Fixed-Dose Combination Versus Olmesartan Medoxomil and Hydrochlorothiazide Fixed-Dose Combination in Hypertensive Subjects With Moderate [NCT01309828]	Phase 3	153 participants (Actual)	Interventional	2011-03-31	Completed
A Prospective, Open Label, Titration Study to Assess the Efficacy and Safety of Benicar® and Benicar ®HCT in Patients With Stage II Systolic Hypertension [NCT00185068]	Phase 4	110 participants	Interventional	2004-03-31	Completed
Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE) [NCT00185185]	Phase 3	165 participants (Actual)	Interventional	2001-11-30	Completed
Supplemental Benefit of Angiotensin II Receptor Blocker in Hypertensive Patients With Stable Heart Failure Using Olmesartan (SUPPORT Trial) [NCT00417222]	Phase 3	1,145 participants (Actual)	Interventional	2006-11-30	Completed
Randomized, Single-Blind, Multicenter, Phase III, Non-Inferiority Clinical Trial to Evaluate the Efficacy and Safety of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension. [NCT05110898]	Phase 3	400 participants (Anticipated)	Interventional	2022-08-01	Not yet recruiting
A Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Triple Fixed Dose Combination Therapy With Olmesartan Medoxomil 20mg, Amlodipine 5mg and Hydrochlorothiazide 12.5mg in Patients With Hypertension Not Controlled With D [NCT01838850]	Phase 3	344 participants (Actual)	Interventional	2013-04-30	Completed
Angiotensin II Blockade and Adipose Tissue Inflammation in Obesity [NCT01684748]	Phase 4	20 participants (Actual)	Interventional	2009-02-28	Completed
National, Multicenter, Open-Label and Prospective Study Assessment of Efficacy and Safety in Stage 1 and 2 Essential Hypertension With Olmesartan Medoxomil Based Treatment Algorithm From Monotherapy to Association With Hydrochlorothiazide and Amlodipine B [NCT00890591]	Phase 4	144 participants (Actual)	Interventional	2006-08-31	Completed
"A Multi-center, Double Blind, Efficacy, and Safety Study of the Oral Angiotensin II Receptor Blocker Olmesartan Medoxomil Versus Losartan in Patients With Mild to Moderate Essential Hypertension" [NCT00857285]	Phase 3	130 participants (Actual)	Interventional	2002-05-31	Completed
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan Medoxomil + Chlorthalidone (40mg + 12.5mg and 40mg + 25mg) Compared With BENICAR HCT® in Hypertension Control [NCT02483936]	Phase 3	348 participants (Anticipated)	Interventional	2023-04-30	Not yet recruiting
An Open-label Study of the Single-dose Pharmacokinetics of Olmesartan Medoxomil in Pediatric Patients With Hypertension [NCT00151814]	Phase 1	24 participants (Actual)	Interventional	2005-09-30	Completed
Efficacy and Safety of a Sequential Therapy Change From Candesartan 32 mg to the Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg in Patients With Poorly Controlled Moderate Hypertension - an Open Phase IV Trial [NCT01611077]	Phase 4	88 participants (Actual)	Interventional	2012-01-31	Completed
A Randomized, Double-blind, Active-controlled, Parallel Group, 52-week Study to Evaluate the Effect of LCZ696 Compared to Olmesartan on Regional Aortic Stiffness in Subjects With Essential Hypertension [NCT01870739]	Phase 2	115 participants (Actual)	Interventional	2013-10-31	Completed
A Multi-center, Randomized, Double-blind, Active-controlled, 8-week Study to Evaluate the Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Patients With Essential Hypertension [NCT01785472]	Phase 3	1,438 participants (Actual)	Interventional	2013-04-30	Completed
Effect of Different Doses of Olmesartan Medoxomil Compared to Losartan on Proteinuria, Renal Function and Inflammatory Markers in Type 2 Diabetics With Nephropathy [NCT00362960]	Phase 3	300 participants	Interventional	2003-05-31	Completed
Lowering Blood Pressure in Primary Care in Vienna [NCT02377661]	Phase 4	229 participants (Actual)	Interventional	2015-03-31	Completed
Effect of Olmesartan or Amlodipine on Serum Angiotensin(1-7) Levels and Vascular Functions in Patients With Type 2 Diabetes and Hypertension [NCT05189015]	Phase 4	80 participants (Actual)	Interventional	2021-01-01	Completed
Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control [NCT02493322]	Phase 3	261 participants (Anticipated)	Interventional	2023-04-30	Not yet recruiting
A Randomized, Double-blind 52-week Study to Evaluate the Safety and Efficacy of an LCZ696 Regimen Compared to an Olmesartan Regimen on Arterial Stiffness Through Assessment of Central Blood Pressure in Elderly Patients With Hypertension [NCT01692301]	Phase 2	454 participants (Actual)	Interventional	2012-12-31	Completed
A Phase I Clinical Trial to Compare and Evaluate Safety and Pharmacokinetic Characteristics After Administration of ATB-101 or Co-administration of ATB-1011 and ATB-1012 in Healthy Adult Volunteers [NCT05017987]	Phase 1	36 participants (Actual)	Interventional	2021-06-19	Completed
A Randomized 8-week Double-blind, Parallel-group, Active-controlled, Multicenter Study to Evaluate Efficacy and Safety of LCZ696 200 mg in Comparison With Olmesartan 20 mg in Essential Hypertensive Patients Not Responsive to Olmesartan [NCT01876368]	Phase 3	376 participants (Actual)	Interventional	2013-09-30	Completed
The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease by Smart Angioplasty Research Team: SMART-ROAD Trial [NCT02516826]	Phase 2	504 participants (Anticipated)	Interventional	2015-08-31	Not yet recruiting
An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of Olmesartan Medoxomil Tablets 40 mg [Torrent,India] Versus Benicar 40 mg Tablets [Daiichi Sankyo Inc., USA] in Healthy Subjects-Fasted Condition [NCT03318354]	Phase 1	34 participants (Actual)	Interventional	2010-05-31	Completed
Dose-ranging Study to Evaluate the Safety and Efficacy of Olmesartan Medoxomil in Children and Adolescents With Hypertension [NCT00151775]	Phase 2/Phase 3	362 participants (Actual)	Interventional	2005-05-31	Completed
Efficacy and Safety of s086 Tablets in the Treatment of Mild to Moderate Essential Hypertension:a Randomized,Double-blind,Placebo-controlled,Multicenter Phase II Clinical Trial [NCT05033535]	Phase 2	10 participants (Anticipated)	Interventional	2020-07-01	Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00141453 (4) [back to overview]	Renal Composite Outcomes
NCT00141453 (4) [back to overview]	Number of Participants Experiencing Cardiovascular Composite Outcomes
NCT00141453 (4) [back to overview]	Reciprocal (1/Serum Creatinine) of Serum Creatinine
NCT00141453 (4) [back to overview]	The Change in Proteinuria
NCT00151775 (6) [back to overview]	Mean Change From Period 3 Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 3
NCT00151775 (6) [back to overview]	Mean Change From Period 3 Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 3
NCT00151775 (6) [back to overview]	Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 4 (End of Study)
NCT00151775 (6) [back to overview]	Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 4 (End of Study)
NCT00151775 (6) [back to overview]	Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 2 (3 Weeks)
NCT00151775 (6) [back to overview]	Least Squares Mean Change From Baseline in Seated Systolic Blood Pressure to the End of Period 2 (3 Weeks)
NCT00151814 (8) [back to overview]	For Olmesartan, the Elimination Half-life of the Drug in Plasma
NCT00151814 (8) [back to overview]	For Olmesartan, the Elimination Constant Rate
NCT00151814 (8) [back to overview]	For Olmesartan, the Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC 0-t)
NCT00151814 (8) [back to overview]	For Olmesartan, the Apparent Oral Volume of Distribution
NCT00151814 (8) [back to overview]	For Olmesartan, the Apparent Oral Clearance
NCT00151814 (8) [back to overview]	For Olmesartan, Area Under the Concentration-time Curve From the Time of the Dose to Infinity
NCT00151814 (8) [back to overview]	Foe Olmesartan, the Time of Maximum Plasma Concentration
NCT00151814 (8) [back to overview]	For Olmesartan, the Maximum Plasma Concentration Over the Entire Sampling Phase
NCT00311155 (6) [back to overview]	Percentage of Participants Who Were Systolic Responders Overall and for Each Treatment From Baseline to the Completion of the Treatment During Which Blood Pressure Goals Were Achieved
NCT00311155 (6) [back to overview]	Percentage of Participants Who Were Diastolic Responders Overall and for Each Treatment From Baseline to the Completion of Treatment During Which Blood Pressure Goals Were Achieved.
NCT00311155 (6) [back to overview]	Percentage of Participants Who Achieved Normalized Blood Pressure Overall and for Each Treatment From Baseline to Completion of the Treatment During Which Blood Pressure Goals Were Achieved
NCT00311155 (6) [back to overview]	Mean Change in Systolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment
NCT00311155 (6) [back to overview]	Mean Change in Diastolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment
NCT00311155 (6) [back to overview]	The Percentage of Participants Treated to Target Blood Pressure Goals Overall and for Each Treatment Step From Baseline to Completion of Treatment During Which the Goal Was Achieved.
NCT00403481 (9) [back to overview]	Change From Baseline to Week 12 in Ambulatory BP Measurement (Systolic)During the Last 4 Hours of the Last (Week 12 ) 24-hour Dosing Period.
NCT00403481 (9) [back to overview]	Change From Baseline to Week 12 in Ambulatory BP Measurement (Systolic)During the Last 6 Hours of the Last (Week 12 ) 24-hour Dosing Period.
NCT00403481 (9) [back to overview]	Change From Baseline to Week 12 in Mean 24-hour Ambulatory BP (Diastolic)
NCT00403481 (9) [back to overview]	Change From Baseline to Week 12 in Systolic BP (SBP) as Measured by 24-hour ABPM.
NCT00403481 (9) [back to overview]	Change in Ambulatory Blood Pressure (Diastolic) From Baseline to Week 12 During the Last 2 Hours of the Last (Week 12 ) 24-hour Dosing Period.
NCT00403481 (9) [back to overview]	Change From Baseline to Week 12 in Mean Daytime and Nighttime Ambulatory Blood Pressure Measurement (Systolic).
NCT00403481 (9) [back to overview]	Change in Ambulatory BP (Diastolic) From Baseline to Week 12 During the Last (Week 12 ) 4 and 6 Hours of the Last 24-hour Dosing Period.
NCT00403481 (9) [back to overview]	Change in Daytime and Nighttime Ambulatory Blood Pressure (Diastolic) From Baseline to Week 12
NCT00403481 (9) [back to overview]	Change From Baseline to Week 12 in Ambulatory BP Measurement (Systolic)During the Last 2 Hours of the Last (Week 12) 24-hour Dosing Period.
NCT00412932 (7) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure After 12 Weeks of Active Treatment.
NCT00412932 (7) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure After 12 Weeks of Active Treatment
NCT00412932 (7) [back to overview]	Change From Baseline in Mean Daytime (8am-4pm) and Mean Nighttime (10 Pm-6am) Ambulatory Blood Pressure Monitored Diastolic Blood Pressure After 12 Weeks of Active Treatment
NCT00412932 (7) [back to overview]	Change From Baseline in Mean Daytime (8am-4pm) and Mean Nighttime (10pm-6am)Ambulatory Systolic Blood Pressure After 12 Weeks of Active Treatment
NCT00412932 (7) [back to overview]	Number of Subjects Who Achieved Mean 24-hour Ambluatory Blood Pressure of <140/90 mm Hg, Systolic Blood Pressure <140 mm Hg, and Diastolic Blood Pressure <90 mm Hg After 12 Weeks of Active Treatment
NCT00412932 (7) [back to overview]	Number of Subjects Who Achieved Mean Daytime (8am - 4pm) Ambulatory Blood Pressure of <140/90 mm Hg, Systolic Blood Pressure <140 mm Hg, and Diastolic Blood Pressure <90 mm Hg After 12 Weeks of Active Treatment.
NCT00412932 (7) [back to overview]	Number of Subjects Who Achieved Mean Nighttime (10pm - 6am) Ambulatory Blood Pressure of <140/90 mm Hg, Systolic Blood Pressure <140 mm Hg, and Diastolic Blood Pressure <90 mm Hg After 12 Weeks of Active Treatment.
NCT00430508 (8) [back to overview]	Change in Mean 24-hour Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.
NCT00430508 (8) [back to overview]	Change in Mean Daytime Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.
NCT00430508 (8) [back to overview]	Change in Mean Night-time Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.
NCT00430508 (8) [back to overview]	Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 12.
NCT00430508 (8) [back to overview]	Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 16
NCT00430508 (8) [back to overview]	Change in Mean Trough Sitting Systolic Blood Pressure From Week 8(Baseline) to Week 12.
NCT00430508 (8) [back to overview]	Change in Mean Trough Sitting Systolic Blood Pressure From Week 8(Baseline) to Week 16.
NCT00430508 (8) [back to overview]	Number of Patients Achieving Target Blood Pressure at Week 16
NCT00430638 (10) [back to overview]	The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Black Participants.
NCT00430638 (10) [back to overview]	Change From Baseline in Mean Systolic Blood Pressure (SBP) After 12 Weeks of Randomized Treatment as Measured by Omron Device.
NCT00430638 (10) [back to overview]	Change From Baseline in Mean Diastolic Blood Pressure (DBP) After 12 Weeks of Randomized Treatment as Measured by Omron Device.
NCT00430638 (10) [back to overview]	The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Non-Black Participants.
NCT00430638 (10) [back to overview]	The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Females.
NCT00430638 (10) [back to overview]	The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Males.
NCT00430638 (10) [back to overview]	The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Stage 2 Hypertensives
NCT00430638 (10) [back to overview]	The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Stage 1 Hypertensives
NCT00430638 (10) [back to overview]	The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Participants Less Than 65 Years Old.
NCT00430638 (10) [back to overview]	The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Participants Greater Than or Equal to 65 Years Old.
NCT00430950 (5) [back to overview]	Change in Mean Trough Sitting Diastolic Blood Pressure
NCT00430950 (5) [back to overview]	Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 12
NCT00430950 (5) [back to overview]	Number of Participants Achieving Blood Pressure Goal.
NCT00430950 (5) [back to overview]	Change in Daytime, Nighttime and 24-hour Blood Pressure Evaluated by Ambulatory Blood Pressure Monitoring 8 Weeks After Baseline.
NCT00430950 (5) [back to overview]	Change in Sitting Systolic Blood Pressure 4 Weeks and 8 Weeks After Baseline.
NCT00523744 (12) [back to overview]	Change in Sitting Pulse Pressure During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Extension Phase of the Study
NCT00523744 (12) [back to overview]	Percentage of Patients Who Achieved Normalized Blood Pressure During the Extension Phase of the Study
NCT00523744 (12) [back to overview]	Percentage of Patients Who Achieved Normalized Blood Pressure During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Extension Phase of the Study
NCT00523744 (12) [back to overview]	Change in Mean Sitting Diastolic Blood Pressure (msDBP) During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Change in Mean Sitting Systolic Blood Pressure (msSBP) During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Extension Phase of the Study
NCT00523744 (12) [back to overview]	Percentage of Patients Who Achieved a Protocol-defined Blood Pressure Response During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Change in Sitting Pulse Rate During the Extension Phase of the Study
NCT00523744 (12) [back to overview]	Change in Sitting Pulse Rate During the Core Phase of the Study
NCT00523744 (12) [back to overview]	Change in Sitting Pulse Pressure During the Extension Phase of the Study
NCT00527514 (6) [back to overview]	Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 5mg + Olmesartan 40 mg Group
NCT00527514 (6) [back to overview]	Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 5mg Group.
NCT00527514 (6) [back to overview]	Change From Baseline in Daytime and Nighttime Ambulatory Systolic Blood Pressure
NCT00527514 (6) [back to overview]	Change From Baseline in Mean 24-hour Systolic Blood Pressure Measured by Ambulatory Monitoring
NCT00527514 (6) [back to overview]	Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 10 mg + Olmesartan 40 mg Group
NCT00527514 (6) [back to overview]	Change From Baseline in Cuff Systolic Blood Pressure for the Amlodipine 5mg + Olmesartan 20 mg Group.
NCT00649389 (4) [back to overview]	Change in Seated Systolic Blood Pressure From Baseline to Week 12
NCT00649389 (4) [back to overview]	Percentage of Subjects Who Reached Blood Pressure Goal (<140/90 mmHg; <130/80 mmHg for Subjects With Diabetes, Chronic Renal Disease, or Chronic Cardiovascular Disease)by 12 Weeks
NCT00649389 (4) [back to overview]	Change in Mean 24-hour Ambulatory Blood Pressure From Baseline to Week 12 or Early Termination
NCT00649389 (4) [back to overview]	Change From Baseline to Week 12 in Seated Diastolic Blood Pressure (SeDBP).
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Nighttime Ambulatory Blood Pressure Thresholds at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Last 2 Hour Ambulatory Blood Pressure Thresholds at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Nighttime Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 3
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 6
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 15
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Daytime Ambulatory Blood Pressure Thresholds at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Daytime Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean 24 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12
NCT00654745 (29) [back to overview]	Change in Mean Seated Systolic Blood Pressure (SeSBP) From Week 0 (Baseline) After 3, 6, 9, 12, 15, and 18 Weeks
NCT00654745 (29) [back to overview]	Change in Mean Seated Diastolic Blood Pressure (SeDBP) From Week 0 (Baseline) After 3, 6, 9, 12, 15, and 18 Weeks
NCT00654745 (29) [back to overview]	Change From Week 0 (Baseline) in Mean 24-hour Ambulatory Blood Pressure Monitoring (ABPM) Systolic Blood Pressure (SBP) After 12 Weeks of Active Treatment
NCT00654745 (29) [back to overview]	Change From Week 0 (Baseline) in Mean ABPM Diastolic Blood Pressure (DBP) After 12 Weeks of Active Treatment
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 18
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 3
NCT00654745 (29) [back to overview]	Change From Week 0 (Baseline) in Mean ABPM SBP After 12 Weeks of Active Treatment
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 9
NCT00654745 (29) [back to overview]	Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 18
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Seated Systolic and Diastolic Blood Pressure Reductions at Week 6
NCT00654745 (29) [back to overview]	Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 9
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean 24-hour Ambulatory Blood Pressure Thresholds at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Seated Systolic and Diastolic Blood Pressure Thresholds at Week 15
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Last 2 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Last 4 Hour Ambulatory Blood Pressure Thresholds at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Last 4 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Last 6 Hour Ambulatory Blood Pressure Thresholds at Week 12
NCT00654745 (29) [back to overview]	Number of Participants Achieving Mean Last 6 Hour Ambulatory Systolic and Diastolic Blood Pressure Reductions at Week 12
NCT00696241 (15) [back to overview]	Change From Baseline in Daytime (6am to 10 pm) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696241 (15) [back to overview]	Change From Baseline in Mean Trough Clinic Sitting Diastolic Blood Pressure
NCT00696241 (15) [back to overview]	Change From Baseline in Mean Trough Clinic Sitting Systolic Blood Pressure
NCT00696241 (15) [back to overview]	Change From Baseline in the 12-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
NCT00696241 (15) [back to overview]	Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696241 (15) [back to overview]	Change From Baseline in the Nighttime (12 am to 6 am) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696241 (15) [back to overview]	Change From Baseline in the Trough (22-24-hr) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696241 (15) [back to overview]	Change From Baseline in the Trough (22-24-hr) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696241 (15) [back to overview]	Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as < 90 mm Hg and/or Reduction From Baseline ≥ 10 mm Hg
NCT00696241 (15) [back to overview]	Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as < 140 mm Hg and/or Reduction From Baseline ≥ 20 mm Hg
NCT00696241 (15) [back to overview]	Change From Baseline in Daytime (6am to 10 pm) Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696241 (15) [back to overview]	Percentage of Participants Who Achieve Both a Clinic Diastolic and Systolic Blood Pressure Response
NCT00696241 (15) [back to overview]	Change From Baseline in the 12-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
NCT00696241 (15) [back to overview]	Change From Baseline in the Nighttime (12 am to 6 am) Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00696241 (15) [back to overview]	Change From Baseline in the 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00791258 (59) [back to overview]	Change in Mean Seated Systolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of African American/Black Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of African American/Black Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Asain Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Asian Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Asian Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Elderly Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Elderly Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Hispanic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Hispanic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Obese Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Obese Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Achieving the Mean 24-hour Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Achieving the Mean Daytime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Achieving the Mean Nighttime Blood Pressure Goals, as Measured by Ambulatory Blood Pressure Monitor, From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Beta Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Dihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	The Percentage of Subjects Who Achieve BP Goal (<140/90 mmHg for Non-diabetics or <130/80 mmHg for Diabetics) From Baseline to 12 and 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Type 2 Diabetic Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients With Metabolic Syndrome Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of African American/Black Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Diuretic Achieving the Blood Pressure Goals From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	The Percentage of Patients Who Achieve Seated Systolic Blood Pressure Goal (<140 mm Hg for Non-diabetics and <130 mm Hg for Diabetics) From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	The Percentage of Subjects Achieving Seated Diastolic BP Goal (<90 mmHg for Non-diabetics or < 80 mmHg for Subjects With Diabetes) From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Change From Baseline to Week 12 in Ambulatory Systolic and Diastolic Blood Pressure Values
NCT00791258 (59) [back to overview]	Change From Baseline to Week 20 in Ambulatory Systolic and Diastolic Blood Pressure Values
NCT00791258 (59) [back to overview]	Change in Mean Seated Diastolic Blood Pressure From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients With Metabolic Syndrome Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients Achieving Seated Systolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients Achieving Seated Diastolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients Achieving Seated Diastolic Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Patients Achieving Seated Blood Pressure Goal From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on an Angiotensin II Receptor Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Type 2 Diabetic Patients Achieving Seated Systolic Blood Pressure Reduction Ranges From Baseline to 4, 8, 12, 16, 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on an Angiotensin Converting Enzyme Inhibitor Achieving the Blood Pressure Goals From Baseline to 12 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 20 Weeks
NCT00791258 (59) [back to overview]	Percentage of Participants Previously on a Nondihydropyridine Calcium Channel Blocker Achieving the Blood Pressure Goals From Baseline to 12 Weeks
NCT00846365 (16) [back to overview]	Change From Baseline in Daytime Mean (6am to 10pm) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline in Daytime Mean (6am to 10pm) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline in 24-hour Mean Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline in 24-hour Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline in 12-hr Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline in 12-hr Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure.
NCT00846365 (16) [back to overview]	Percentage of Participants Who Achieve a Clinic Systolic Blood Pressure Response, Defined as <140 mm Hg for Participants Without Diabetes or CKD or <130 mm Hg for Participants With Diabetes or CKD
NCT00846365 (16) [back to overview]	Change From Baseline to Week 4 in Trough, Sitting, Clinic Systolic Blood Pressure.
NCT00846365 (16) [back to overview]	Change From Baseline in Nighttime Mean (12am to 6am) Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline in Nighttime Mean (12am to 6am) Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring
NCT00846365 (16) [back to overview]	Change From Baseline in Trough Mean Diastolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline in Trough Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.
NCT00846365 (16) [back to overview]	Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure
NCT00846365 (16) [back to overview]	Percentage of Participants Who Achieve a Clinic Diastolic AND Systolic Blood Pressure Response, Defined as <140/90 mm Hg for Participants Without Diabetes or Chronic Kidney Disease (CKD) or <130/80 mm Hg for Participants With Diabetes or CKD
NCT00846365 (16) [back to overview]	Percentage of Participants Who Achieve a Clinic Diastolic Blood Pressure Response, Defined as Defined as <90 mm Hg for Participants Without Diabetes or CKD or <80 mm Hg for Participants With Diabetes or CKD
NCT00857285 (1) [back to overview]	Mean Change of Sitting dBP From Baseline to Week 12
NCT00858702 (3) [back to overview]	The Percentage of Patients Achieving Target Sitting Blood Pressure of Less Than 130/85
NCT00858702 (3) [back to overview]	Percentage of Patients With Drug-related Adverse Events (Subjective Symptoms/Objective Findings)
NCT00858702 (3) [back to overview]	Percent of Patients With Drug-related Adverse Events (Laboratory Changes in Clinical Laboratory Values)
NCT00890591 (4) [back to overview]	Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 in First Titrated Group (Olmesartan 20 mg + 12.5 mg Hydrochlorothiazide)
NCT00890591 (4) [back to overview]	Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 in Third Titrated Group (Olmesartan + Hydrochorothiazide + Amlodipine)
NCT00890591 (4) [back to overview]	Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 in Second Titrated Group (Olmesartan 40 mg + 25 mg Hydrochlorothiazide)
NCT00890591 (4) [back to overview]	Number of Patients That Achieved a Blood Pressure Goal of Less Than 130/85 (Olmesartan 20 mg Monotherapy)
NCT00902538 (10) [back to overview]	Change in 24-hour Systolic Blood Pressure Assessed by 24-hour Ambulatory Blood Pressure Measurement.
NCT00902538 (10) [back to overview]	Change in Seated Diastolic Blood Pressure (SeDBP) of the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg vs. OM/AML 40/10 mg
NCT00902538 (10) [back to overview]	In Non-responders, the Change in 24-hour Diastolic Blood Pressure Assessed by 24-hour Ambulatory Blood Pressure Measurement.
NCT00902538 (10) [back to overview]	In Non-responders, the Change in 24-hour Systolic Blood Pressure Assessed by 24-hour Ambulatory Blood Pressure Measurement.
NCT00902538 (10) [back to overview]	In Non-responders, the Change in Seated Diastolic Blood Pressure Associated With the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg.
NCT00902538 (10) [back to overview]	In Non-responders, the Change in Seated Systolic Blood Pressure Associated With the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg.
NCT00902538 (10) [back to overview]	Change in Seated Systolic Blood Pressure (SeSBP) of the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg vs. OM/AML 40/10 mg
NCT00902538 (10) [back to overview]	Number of Subjects Achieving Blood Pressure (BP) Goal at Week 16.
NCT00902538 (10) [back to overview]	Change in 24-hour Diastolic Blood Pressure (DBP) Assessed by 24-hour Ambulatory Blood Pressure Measurement (ABPM).
NCT00902538 (10) [back to overview]	In Non-responders, the Number of Subject Meeting Their Blood Pressure Goals Associated With the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg.
NCT00923091 (10) [back to overview]	Change in Seated Diastolic Blood Pressure From Week 22 to Week 26
NCT00923091 (10) [back to overview]	Change in Seated Diastolic Blood Pressure From Week 18 to Week 22
NCT00923091 (10) [back to overview]	Change in Seated Diastolic Blood Pressure (SeDBP).
NCT00923091 (10) [back to overview]	Change in Seated Systolic Blood Pressure (SeDBP) During Open-Label Period VI (Titration Effect From OM/AML/HCTZ 40/5/25 to 40/10/25.
NCT00923091 (10) [back to overview]	Change in Seated Systolic Blood Pressure (SeDBP).
NCT00923091 (10) [back to overview]	Change in Seated Systolic Blood Pressure From Week 18 to Week 22
NCT00923091 (10) [back to overview]	Change in Seated Systolic Blood Pressure From Week 22 to Week 26
NCT00923091 (10) [back to overview]	Number of Subjects Reaching Blood Pressure Goal at Week 10
NCT00923091 (10) [back to overview]	Number of Subjects Reaching Blood Pressure Goal at Week 26
NCT00923091 (10) [back to overview]	Number of Subjects Reaching Blood Pressure Goal From Week 18 to Week 22
NCT00949884 (16) [back to overview]	Incremental Change From Week 4 to Week 8 in Trough, Cuff, Seated Systolic Blood Pressure (SSBP)
NCT00949884 (16) [back to overview]	Change From Baseline in Mean 24-Hour Ambulatory Blood Pressure at Week 4
NCT00949884 (16) [back to overview]	Change From Baseline in Mean 24-Hour Ambulatory Blood Pressure at Week 8
NCT00949884 (16) [back to overview]	Change From Baseline in Mean Ambulatory Blood Pressure During the Final 2, 4, and 6 Hours of the Dosing Interval at Week 4
NCT00949884 (16) [back to overview]	Change From Baseline in Mean Ambulatory Blood Pressure During the Final 2, 4, and 6 Hours of the Dosing Interval at Week 8
NCT00949884 (16) [back to overview]	Change From Baseline in Mean Daytime (8am to 4pm) and Mean Nighttime (10pm to 6am) Ambulatory Blood Pressure at Week 4
NCT00949884 (16) [back to overview]	Change From Baseline in Mean Daytime (8am to 4pm) and Mean Nighttime (10pm to 6am) Ambulatory Blood Pressure at Week 8
NCT00949884 (16) [back to overview]	Change From Baseline to Week 2 in Trough, Cuff, Seated Blood Pressure
NCT00949884 (16) [back to overview]	Percentage of Participants Achieving Ambulatory Blood Pressure Goal of < 135/85 mmHg at Week 8
NCT00949884 (16) [back to overview]	Percentage of Participants Achieving Blood Pressure Goals at Week 4
NCT00949884 (16) [back to overview]	Percentage of Participants Achieving Blood Pressure Goals at Week 8
NCT00949884 (16) [back to overview]	Change From Baseline to Week 4 in Trough, Cuff, Seated Diastolic Blood Pressure (SDBP)
NCT00949884 (16) [back to overview]	Change From Baseline to Week 4 in Trough, Cuff, Seated Systolic Blood Pressure (SSBP)
NCT00949884 (16) [back to overview]	Change From Baseline to Week 8 in Trough, Cuff, Seated Diastolic Blood Pressure (SDBP)
NCT00949884 (16) [back to overview]	Change From Baseline to Week 8 in Trough, Cuff, Seated Systolic Blood Pressure (SSBP)
NCT00949884 (16) [back to overview]	Incremental Change From Week 4 to Week 8 in Trough, Cuff, Seated Diastolic Blood Pressure (SDBP)
NCT00996281 (2) [back to overview]	Percentage of Participants With at Least 1 Adverse Event
NCT00996281 (2) [back to overview]	Percentage of Participants With Serum Creatinine Elevations Greater Than 50% From Baseline and Greater Than the Upper Limit of Normal (ULN)
NCT01033071 (18) [back to overview]	Percentage of Participants Who Reached Target Clinic Systolic Blood Pressure of <140 mm Hg and/or Reduction of ≥20 mm Hg From Baseline.
NCT01033071 (18) [back to overview]	Percent of Participants Who Reached Target Clinic Systolic Blood Pressure of <140 mm Hg and/or Reduction of ≥20 mm Hg From Baseline and Target Clinic Diastolic Blood Pressure of <90 mm Hg and/or Reduction of ≥10 mm Hg From Baseline.
NCT01033071 (18) [back to overview]	Change From Baseline in 24-hour Mean Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Mean Nighttime (12 AM to 6 AM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Mean Nighttime (12 AM to 6 AM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Mean Daytime (6 AM to 10 PM) Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Mean Daytime (6 AM to 10 PM) Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in 24-hour Mean Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Percentage of Participants Who Reached Target Clinic Diastolic Blood Pressure of <90 mm Hg and/or Reduction of ≥10 mm Hg From Baseline.
NCT01033071 (18) [back to overview]	Change From Baseline in Mean Trough Systolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.
NCT01033071 (18) [back to overview]	Change From Baseline in Trough, Sitting, Clinic Diastolic Blood Pressure.
NCT01033071 (18) [back to overview]	Change From Baseline in the Mean Systolic Blood Pressure During Each Hour of the 24-hour Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in the Mean Diastolic Blood Pressure During Each Hour of the 24-hour Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Trough, Sitting, Clinic Systolic Blood Pressure.
NCT01033071 (18) [back to overview]	Change From Baseline in the Mean Systolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in the Mean Diastolic Blood Pressure at 0 to 12 Hours After Dosing by Ambulatory Blood Pressure Monitoring.
NCT01033071 (18) [back to overview]	Change From Baseline in Mean Trough Diastolic Blood Pressure by Ambulatory Blood Pressure Monitoring.
NCT01200407 (4) [back to overview]	Percentage of Participants Achieving JNC VII Recommended Blood Pressure Goal at Week 12 With LOCF
NCT01200407 (4) [back to overview]	Change From Baseline in SBP and DBP at Week 12 With Last Observation Carried Forward (LOCF)
NCT01200407 (4) [back to overview]	Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Weeks 4, 8 and 12 Without (w/o) LOCF
NCT01200407 (4) [back to overview]	Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT01309828 (4) [back to overview]	Percentage of Participants at Final Visit Who Achieve Target Systolic Blood Pressure <130 mm Hg
NCT01309828 (4) [back to overview]	Percentage of Participants at Final Visit Who Achieved Both a Clinic Systolic and Diastolic Blood Pressure Response
NCT01309828 (4) [back to overview]	Percentage of Participants at Final Visit Who Achieved Target Diastolic Blood Pressure <80 mm Hg
NCT01309828 (4) [back to overview]	Number of Participants With at Least 1 Adverse Event (AE)
NCT01684748 (2) [back to overview]	Insulin Sensitivity by Intravenous Glucose Tolerance Testing (Change Over Time)
NCT01684748 (2) [back to overview]	Collagen Gene Expression in Skeletal Muscle (Change Over Time)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean 24-hour Systolic Blood Pressure (maSBP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean 24-hour Diastolic Blood Pressure (maDBP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory Pulse Pressure (maPP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 52 Weeks
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Central Aortic Systolic Pressure (CASP) at 12 Weeks
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Sitting Pulse Pressure (msPP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Pulse Wave Velocity (PWV)
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Central Pulse (CPP) Pressure
NCT01692301 (11) [back to overview]	Change From Baseline in Mean Arterial Pressure (MAP)
NCT01785472 (13) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory Blood Pressure
NCT01785472 (13) [back to overview]	Number of Patients With Adverse Events, Serious Adverse Events, and Death as Assessment of Safety and Tolerability
NCT01785472 (13) [back to overview]	Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Dippers.
NCT01785472 (13) [back to overview]	Sub-group Analysis for Change From Baseline in Mean Ambulatory Diastolic Blood Pressure in Non-dippers.
NCT01785472 (13) [back to overview]	Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Dippers.
NCT01785472 (13) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 400 mg Versus Olmesartan 20 mg
NCT01785472 (13) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) Between LCZ696 200, and LCZ696 400 mg Versus Olmesartan 20 mg
NCT01785472 (13) [back to overview]	Change From Baseline in Ambulatory Pulse Pressure
NCT01785472 (13) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Between LCZ696 200 mg Versus Olmesartan 20 mg
NCT01785472 (13) [back to overview]	Sub-group Analysis for Change From Baseline in Mean Ambulatory Systolic Blood Pressure in Non-dippers.
NCT01785472 (13) [back to overview]	Change From Baseline in Office Pulse Pressure (msPP)
NCT01785472 (13) [back to overview]	Number of Patients Achieving Successful Blood Pressure Control
NCT01785472 (13) [back to overview]	Number of Responders
NCT01870739 (10) [back to overview]	Change From Baseline in Augmentation Index at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Ascending Aorta Distensibility at 52 Week
NCT01870739 (10) [back to overview]	Change From Baseline in Distal Descending Aorta Distensibility at 52 Weeks
NCT01870739 (10) [back to overview]	Number of Patients With Reported Adverse Events, Serious Adverse Events and Death
NCT01870739 (10) [back to overview]	Change From Baseline in Local Aortic Strain at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Central Blood Pressure at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Regional Aortic Pulse Wave Velocity at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Proximal Descending Aorta Distensibility at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Carotid-femoral Pulse Wave Velocity at 52 Weeks
NCT01870739 (10) [back to overview]	Change From Baseline in Augmentation Pressure at 52 Weeks
NCT01876368 (11) [back to overview]	Change From Baseline in 24-hour Mean Ambulatory Systolic Blood Pressure (maSBP)
NCT01876368 (11) [back to overview]	Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure (maDBP)
NCT01876368 (11) [back to overview]	Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP)
NCT01876368 (11) [back to overview]	Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)
NCT01876368 (11) [back to overview]	Change From Baseline in Office Pulse Pressure
NCT01876368 (11) [back to overview]	Number of Patients Achieving Successful Mean Sitting Diastolic Blood Pressure (msDBP) Control
NCT01876368 (11) [back to overview]	Number of Patients Achieving Successful Mean Sitting Diastolic Blood Pressure (msDBP) Response
NCT01876368 (11) [back to overview]	Number of Patients Achieving Successful Mean Sitting Systolic Blood Pressure (msSBP) Response
NCT01876368 (11) [back to overview]	Number of Patients Achieving Successful Overall Blood Pressure Control
NCT01876368 (11) [back to overview]	Number of Patients With Total Adverse Events, Serious Adverse Events and Death
NCT01876368 (11) [back to overview]	Number of Patients Achieving Successful Mean Sitting Systolic Blood Pressure (msSBP) Control

Renal Composite Outcomes

first occurrence of any of the following events: Doubling of serum creatinine level; Death; End stage renal disease (NCT00141453)
Timeframe: Randomization to 5 years

Intervention	participants (Number)
Olmesartan Medoxomil	116
Placebo Comparator	129

Intervention	Median percentage change in ratio (Number)
	12-week value	48-week value	144 -week value
Olmesartan Medoxomil	-19.5	-20.0	-24.9
Placebo Comparator	12.6	6.9	3.1

Intervention	mm Hg (Mean)
	Seated Systolic Blood Pressure	Seated Diastolic Blood Pressure
Cohort C: OM Period 3	1.36	0.31
Cohort C: Placebo Period 3	4.95	3.77

Intervention	mm Hg (Mean)
	Change in Systolic Blood Pressure	Change in Diastolic Blood Pressure
Cohort A: OM Period 3	0.43	0.24
Cohort A: Placebo Period 3	4.93	4.43
Cohort B: OM Period 3	1.37	1.94
Cohort B: Placebo Period 3	3.79	3.25
Cohorts A + B: OM Period 3	0.77	0.85
Cohorts A + B: Placebo Period 3	4.50	3.99

Intervention	mm Hg (Mean)
	Change in Systolic Blood Pressure	Change in Diastolic Blood Pressure
Cohort C: OM (Olmesartan Medoxomil)	-15.7	-13.3

Intervention	mm Hg (Mean)
	Change in Systolic Blood Pressure	Change in Diastolic Blood Pressure
Cohort A: Period 4 Open-label OM	-10.8	-7.4
Cohort B: Period 4 Open-label OM	-7.7	-5.1
Cohorts A + B: Period 4 Open-label OM	-9.7	-6.6

Intervention	mm Hg (Mean)
	Change in Systolic Blood Pressure	Change in Diastolic Blood Pressure
Cohort A: High Dose OM	-12.58	-9.50
Cohort A: Low Dose OM	-7.76	-5.52
Cohort B: High Dose OM	-10.68	-7.58
Cohort B: Low Dose OM	-4.73	-3.49
Cohorts A + B: High Dose OM	-11.87	-8.78
Cohorts A + B: Low Dose OM	-6.63	-4.76

Intervention	mm Hg (Least Squares Mean)
	Non-weight adjusted dosage	Weight adjusted dosage
Cohort A	-0.69	-8.97
Cohort B	-0.85	-7.17
Cohorts A + B	-0.75	-8.36

Intervention	hr (Mean)
6-12 Years of Age Olmesartan Group	8.4
13-16 Years of Age Olmesartan Group	9.1

Intervention	L/hr (Mean)
6-12 Years of Age Olmesartan Group	0.090
13-16 Years of Age Olmesartan Group	0.079

Intervention	ng/mL*hr (Mean)
6-12 Years of Age Olmesartan Group	7874
13-16 Years of Age Olmesartan Group	5851

Intervention	L (Mean)
6-12 Years of Age Olmesartan Group	50.9
13-16 Years of Age Olmesartan Group	81.3

Intervention	ng/mL*hr (Mean)
6-12 Years of Age Olmesartan Group	7988
13-16 Years of Age Olmesartan Group	5982

Intervention	ng/mL (Mean)
6-12 Years of Age Olmesartan Group	1227
13-16 Years of Age Olmesartan Group	895

Intervention	Percentage of Participants (Number)
	Overall N=691	OLM 20 mg N=688	OLM 20 mg + HCTZ 12.5 mg N=580	OLM 20 mg + HCTZ 25 mg N=446	OLM 20 mg + HCTZ 25 mg + AML 5 mg N=296	OLM 20 mg + HCTZ 25 mg + AML 10 mg N=176
Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed	92.6	34.2	49.6	46.6	33.3	20.5

Intervention	Percentage of participants (Number)
	Overall N=691	OLM 20 mg N=688	OLM 20 mg+HCTZ 12.5 mg N=580	OLM 20 mg+HCTZ 25 mg N=446	OLM 20 mg+HCTZ 25 mg+AML 5 mg N=296	OLM 20 mg+HCTZ 25 mg+AML 10 mg N=176
Olmesartan+Hydrochlorothiazide,if Needed+Amlodipine, if Needed	71.8	12.3	16.4	19.2	14.9	8.5

Intervention	participants (Number)
	BP<140/90 mm Hg	SBP<140 mm Hg	DBP<90 mm Hg
Overall Study	133	133	149

Intervention	mm Hg (Mean)
OM/HCTZ 40/25mg + 20/12.5 Matching Placebo	-7.2
OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo	-5.3
OM/HCTZ 20/12.5mg + 40/0 Matching Placebo	-4.1
OM/HCTZ 40/0mg + 20/12.5 Matching Placebo	-2.0

Intervention	mm Hg (Mean)
OM/HCTZ 40/25mg + 20/12.5 Matching Placebo	-7.0
OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo	-5.5
OM/HCTZ 20/12.5mg + 40/0 Matching Placebo	-4.0
OM/HCTZ 40/0mg + 20/12.5 Matching Placebo	-1.8

Intervention	mm Hg (Mean)
OM/HCTZ 40/25mg + 20/12.5 Matching Placebo	-7.9
OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo	-4.5
OM/HCTZ 20/12.5mg + 40/0 Matching Placebo	-4.2
OM/HCTZ 40/0mg + 20/12.5 Matching Placebo	-2.3

Intervention	mm Hg (Mean)
OM/HCTZ 40/25mg + 20/12.5 Matching Placebo	-8.74
OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo	-7.72
OM/HCTZ 20/12.5mg + 40/0 Matching Placebo	-6.66
OM/HCTZ 40/0mg + 20/12.5 Matching Placebo	-4.47

olmesartan medoxomil

Description

Cross-References

Synonyms (154)

Research Excerpts

Overview

Effects

Treatment

Toxicity

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Drug Classes (1)

Pathways (3)

Protein Targets (28)

Potency Measurements

Inhibition Measurements

Other Measurements

Biological Processes (174)

Molecular Functions (68)

Ceullar Components (41)

Bioassays (106)

Research

Studies (450)

Market Indicators

Research Demand Index: 100.33

Study Types

Clinical Trials (102)

Trial Overview

Trial Outcomes

Renal Composite Outcomes

Number of Participants Experiencing Cardiovascular Composite Outcomes

Reciprocal (1/Serum Creatinine) of Serum Creatinine

The Change in Proteinuria

Mean Change From Period 3 Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 3

Mean Change From Period 3 Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 3

Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 4 (End of Study)

Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 4 (End of Study)

Mean Change From Baseline in Seated Systolic and Diastolic Blood Pressure Measurements to the End of Period 2 (3 Weeks)

Least Squares Mean Change From Baseline in Seated Systolic Blood Pressure to the End of Period 2 (3 Weeks)

For Olmesartan, the Elimination Half-life of the Drug in Plasma

For Olmesartan, the Elimination Constant Rate

For Olmesartan, the Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC 0-t)

For Olmesartan, the Apparent Oral Volume of Distribution

For Olmesartan, the Apparent Oral Clearance

For Olmesartan, Area Under the Concentration-time Curve From the Time of the Dose to Infinity

Foe Olmesartan, the Time of Maximum Plasma Concentration

For Olmesartan, the Maximum Plasma Concentration Over the Entire Sampling Phase

Percentage of Participants Who Were Systolic Responders Overall and for Each Treatment From Baseline to the Completion of the Treatment During Which Blood Pressure Goals Were Achieved

Percentage of Participants Who Were Diastolic Responders Overall and for Each Treatment From Baseline to the Completion of Treatment During Which Blood Pressure Goals Were Achieved.

Percentage of Participants Who Achieved Normalized Blood Pressure Overall and for Each Treatment From Baseline to Completion of the Treatment During Which Blood Pressure Goals Were Achieved

Mean Change in Systolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment

Mean Change in Diastolic Blood Pressure Overall and for Each Treatment From Baseline to the Completion of the Treatment

The Percentage of Participants Treated to Target Blood Pressure Goals Overall and for Each Treatment Step From Baseline to Completion of Treatment During Which the Goal Was Achieved.

Change From Baseline to Week 12 in Ambulatory BP Measurement (Systolic)During the Last 4 Hours of the Last (Week 12 ) 24-hour Dosing Period.

Change From Baseline to Week 12 in Ambulatory BP Measurement (Systolic)During the Last 6 Hours of the Last (Week 12 ) 24-hour Dosing Period.

Change From Baseline to Week 12 in Mean 24-hour Ambulatory BP (Diastolic)

Change From Baseline to Week 12 in Systolic BP (SBP) as Measured by 24-hour ABPM.

Change in Ambulatory Blood Pressure (Diastolic) From Baseline to Week 12 During the Last 2 Hours of the Last (Week 12 ) 24-hour Dosing Period.

Change From Baseline to Week 12 in Mean Daytime and Nighttime Ambulatory Blood Pressure Measurement (Systolic).

Change in Ambulatory BP (Diastolic) From Baseline to Week 12 During the Last (Week 12 ) 4 and 6 Hours of the Last 24-hour Dosing Period.

Change in Daytime and Nighttime Ambulatory Blood Pressure (Diastolic) From Baseline to Week 12

Change From Baseline to Week 12 in Ambulatory BP Measurement (Systolic)During the Last 2 Hours of the Last (Week 12) 24-hour Dosing Period.

Change From Baseline in Mean 24-hour Ambulatory Diastolic Blood Pressure After 12 Weeks of Active Treatment.

Change From Baseline in Mean 24-hour Ambulatory Systolic Blood Pressure After 12 Weeks of Active Treatment

Change From Baseline in Mean Daytime (8am-4pm) and Mean Nighttime (10 Pm-6am) Ambulatory Blood Pressure Monitored Diastolic Blood Pressure After 12 Weeks of Active Treatment

Change From Baseline in Mean Daytime (8am-4pm) and Mean Nighttime (10pm-6am)Ambulatory Systolic Blood Pressure After 12 Weeks of Active Treatment

Number of Subjects Who Achieved Mean 24-hour Ambluatory Blood Pressure of <140/90 mm Hg, Systolic Blood Pressure <140 mm Hg, and Diastolic Blood Pressure <90 mm Hg After 12 Weeks of Active Treatment

Number of Subjects Who Achieved Mean Daytime (8am - 4pm) Ambulatory Blood Pressure of <140/90 mm Hg, Systolic Blood Pressure <140 mm Hg, and Diastolic Blood Pressure <90 mm Hg After 12 Weeks of Active Treatment.

Number of Subjects Who Achieved Mean Nighttime (10pm - 6am) Ambulatory Blood Pressure of <140/90 mm Hg, Systolic Blood Pressure <140 mm Hg, and Diastolic Blood Pressure <90 mm Hg After 12 Weeks of Active Treatment.

Change in Mean 24-hour Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.

Change in Mean Daytime Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.

Change in Mean Night-time Ambulatory Blood Pressure Monitoring Diastolic Blood Pressure From Week 8(Baseline) to Week 16.

Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 12.

Change in Mean Trough Sitting Diastolic Blood Pressure From Week 8(Baseline) to Week 16

Change in Mean Trough Sitting Systolic Blood Pressure From Week 8(Baseline) to Week 12.

Change in Mean Trough Sitting Systolic Blood Pressure From Week 8(Baseline) to Week 16.

Number of Patients Achieving Target Blood Pressure at Week 16

The Difference in the Change From Baseline to Week 12 in Seated Systolic and Diastolic Blood Pressure Between the Olmesartan Group and the Placebo Group for Black Participants.

Intervention	mm Hg (Mean)
OM/HCTZ 40/25mg + 20/12.5 Matching Placebo	-11.16
OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo	-9.13
OM/HCTZ 20/12.5mg + 40/0 Matching Placebo	-8.10
OM/HCTZ 40/0mg + 20/12.5 Matching Placebo	-5.66

Intervention	mm Hg (Mean)
OM/HCTZ 40/25mg + 20/12.5 Matching Placebo	-13.16
OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo	-10.90
OM/HCTZ 20/12.5mg + 40/0 Matching Placebo	-9.65
OM/HCTZ 40/0mg + 20/12.5 Matching Placebo	-6.60

Intervention	mm Hg (Mean)
OM/HCTZ 40/25mg + 20/12.5 Matching Placebo	-16.17
OM/HCTZ 40/12.5mg + 20/12.5 Matching Placebo	-13.52
OM/HCTZ 20/12.5mg + 40/0 Matching Placebo	-11.46
OM/HCTZ 40/0mg + 20/12.5 Matching Placebo	-8.85

Intervention	mm Hg (Least Squares Mean)
	Systolic blood pressure	Diastolic blood pressure
Olmesartan vs. Placebo	-21.3	-12.5

Intervention	mm Hg (Mean)
OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo	-11.16
OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo	-10.45

Intervention	mm Hg (Mean)
OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo	-9.32
OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo	-8.83

Intervention	mm Hg (Mean)
	Change from Week 8 to Wk 16 in mean 24-hr ABPM dBP	Change from Week 8 to wk16 in daytime ABPM dBP	Change from Week 8 to wk16 in nighttime ABPM dBP	Change from Week 8 to wk16 in mean 24-hr ABPM sBP	Change from Week 8 to wk16 in daytime ABPM sBP	Change from Week 8 to wk16 in nighttime ABPM sBP
OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo	-7.6	-7.7	-7.0	-12.0	-12.3	-10.7
OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo	-9.2	-9.3	-8.6	-14.7	-15.0	-13.4

Intervention	mm Hg (Mean)
	Change from baseline (Week 8) to Week 16 in sBP	Change from baseline (Week 8) to Week 12 in sBP
OM/HCTZ 20/25 mg + 40/25 mg Matching Placebo	-17.09	-13.80
OM/HCTZ 40/25 mg + 20/25 mg Matching Placebo	-17.41	-14.07

Intervention	Percentage of participants (Number)
	msSBP < 140 mmHg	msDBP < 90 mmHg
Amlodipine+Valsartan+HCTZ - Phase 3	59.3	83.5

Intervention	Percentage of participants (Number)
	msSBP < 140 mmHg	msDBP < 90 mmHg
Amlodipine+Valsartan - Phase 2	44.6	72.6